Document:

EX-10.7

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

Exhibit 10.7 
 Execution Copy

 MASTER CLINICAL TRIAL AGREEMENT 

This Master Clinical Trial Agreement (this “Agreement”) is entered into as of December 1, 2016 (the “Effective Date”),
by and between Immatics US, Inc. (“Sponsor”), having a principal place of business at 2130 Holcombe, Suite 11.3000, Houston, Texas 77030 and The University of Texas MD Anderson Cancer Center (“Study Site”), an
agency of the State of Texas and a member institution of The University of Texas System (“System”), located at 1515 Holcombe Blvd., Houston, Texas 77030. Sponsor and the Study Site are sometimes referred to herein individually as a
“Party” and collectively as “Parties.” 
 PREAMBLE: 

WHEREAS, Sponsor is a immunotherapy company researching and developing new investigational drugs that include, but are not limited to, cell therapies
called ACTologTM, ACTengineTM, and ACTalloTM; 

WHEREAS, Sponsor seeks to and will act as the sponsor for clinical trials performed at the Study Site 

(individually, a “Study” or, collectively, the “Studies”); 

WHEREAS, Sponsor and Study Site are parties to an agreement entitled Collaboration and License Agreement, dated August 14, 2015, under
which Sponsor and Study Site are conducting certain related research and clinical development activities (hereafter referred to as the “Collaboration Agreement”); 

WHEREAS, the investigator for each Study will be an employee of the Study Site (the “Investigator”) and will act as a principal
investigator for the Study; 
 NOW THEREFORE, it is agreed as follows: 
  

	1.	 Subject and Scope of Agreement 

 

	 	1.1	 The Agreement will govern the performance of Studies by Study Site and one or more Investigator(s) on the basis
of Study specific documents (“Work Orders”) as agreed upon by the Parties. This Agreement will apply to all Studies performed by Study Site and the Investigator(s) responsible for the performance of such Studies as set forth in Work
Orders during the term of this Agreement. Each Work Order shall have a unique number to set it apart from all others and shall be substantially in the form as illustrated in Exhibit A. The Work Order will detail the specifics of the
Study to be performed under such Work Order including, without limitation: (a) the protocol to be followed for the Study (“Study Protocol”); (b) the name of the Investigator; and (c) the agreed upon budget for the
performance of the Study (“Study Budget”). Each such Work Order will be attached to this Agreement and will be incorporated herein by reference. 

 

	 	1.2	 In the event of any conflict of terms of this Agreement and the terms of a Work Order, the terms of this
Agreement will govern, unless the Work Order specifically and expressly supersedes this Agreement with respect to a specific term, and then only with respect to the particular Work Order and specific term. 

  
 Page 1 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

Execution Copy 
  

	2.	 Responsibilities of Study Site 

 

	 	2.1	 The Study Site shall conduct each Study in compliance with the Study Protocol, as amended, the
Investigator’s Brochure, and all other applicable laws, regulations, and generally accepted recommendations and guidelines, including without limitation the ICH-GCP Guidelines, the Declaration of Helsinki
as applicable. The Study Site shall reasonably comply with all instructions concerning the Study made by Sponsor and/or any CRO engaged by Sponsor to be in charge of the Study or Studies (“CRO”). 

 

	 	2.2	 The Study Site shall ensure the required experience, capability and resources, sufficient personnel and
equipment, as necessary to perform each Study efficiently and expeditiously in a professional and competent manner, and in adherence to the Protocol. It shall carry out all acts required to perform each Study at the Study Site and shall at all times
devote the necessary personnel and equipment to perform the Studies. 

  

	3.	 Responsibilities of Investigator 

 

	 	3.1	 The Study Site delegates to the Investigator the task of day-to-day conduct and ensuring the supervision of each Study at the Study Site. The Investigator may be assisted in the performance of his obligations by adequate and qualified collaborators and supporting
staff from the Study Site (“Study Team”). 

  

	 	3.2	 The Investigator shall conduct the Study in compliance with the Study Protocol, as amended, the
Investigator’s Brochure, and all other applicable laws, regulations, and generally accepted recommendations and guidelines, including without limitation the ICH-GCP Guidelines, the Declaration of Helsinki
as applicable. The Investigator shall reasonably comply with all instructions concerning the Study made by Sponsor and/or the CRO. 

  

	4.	 Conduct of Studies at the Study Site 

 

	 	4.1	 The Work Order and Study Protocol for each Study conducted pursuant to this Agreement, its appendices and all
future amendments, shall form a part of this Agreement. The Study Protocol and the Investigator’s Brochure may not be amended without the prior written consent of Sponsor and, if required, a subsequent review and approval by the Institutional
Review Board (“IRB”) for conduct of the Study, or by the Study Site’s IRB as applicable. 

  

	 	4.2	 The Study Site shall only start Study subject recruitment once (a) approval of a Study by the responsible
IRB and competent health authorities has been received, (b) the Study initiation visit has been carried out by Sponsor or the CRO, and (c) the Study start was expressly approved by Sponsor. The Study Site shall carefully inform each
patient intended to be enrolled in the Study by Study Site about the aim, benefit and risks of the Study. Only after all of the patient’s questions have been answered and the patient has given written informed consent on the form for patient
information and informed consent (as approved by the Study Site’s IRB and competent health authorities) may the patient be enrolled in the Study. 

  

	 	4.3	 Sponsor or the CRO shall make all required notifications to the competent health authorities (and local health
authorities if applicable). If required, the Study Site shall obtain further approvals requested locally for the conduct of each Study from its own IRB and other academic or administrative committees as applicable. 

  
 Page 2 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

Execution Copy 
  

	 	4.4	 The Study Site and Investigator shall allow Sponsor and CRO employees, auditors and competent health authority
representatives during regular business hours to monitor the execution of each Study at the Study Site and to inspect Study performance at Study Site’s facilities and review and copy all data, records and work products arising from conduct of
the applicable Study. The Study Site and the Investigator shall provide Sponsor and CRO employees with adequate space for work and shall allow access to all Study documents, taking into account all relevant data protection laws, and, to the extent
permitted by law and by Study Site’s and Study Site’s IRB policies, to make copies of the documents in physical or electronic format and forward them to Sponsor or the CRO. In order to protect the confidentiality of patient data, Sponsor
employees and the CRO and auditors shall undertake appropriate measures to keep any such information confidential. During the visit, adequate time for a conversation with the Investigator and other members of the Study Team (if required) to resolve
any Study related questions shall be provided by the Study Site. The Study Site and the Investigator shall allow Sponsor’s and CRO’s employees sufficient time for routine monitoring of activities being performed as part of the Study. These
routine monitoring visits will be performed periodically over the course of the Study (e.g., every month after the first patient visit). 

  

	 	4.5	 The Study Site and the Investigator shall reasonably and timely document, file and store all Study data and
documents in compliance with requirements of applicable laws and regulations. The following shall also apply: 

  

	 	4.5.1	 The Study Site shall obtain from each Study subject a signed informed consent form, as approved by the Sponsor
or the CRO and Study Site’s IRB; 

  

	 	4.5.2	 The Study Site shall prepare and maintain complete, accurate records (in electronic or hardcopy form) for the
Study, in accordance with the Study Protocol; 

  

	 	4.5.3	 The Study Site shall prepare, review for accuracy and completeness, and provide to Sponsor or the CRO of all
original case report forms (“CRFs”, in electronic or hardcopy form) for each Study subject as provided in the Study Protocol; data shall be entered into the Study subjects’ CRF within a reasonable time after each Study visit
(i.e., within 5 business days) by authorized Study Site staff members. Upon request by Sponsor or the CRO regarding questions about or the need to clarify data reported by the Study Site on a patient’s CRF, Study Site agrees to promptly
respond to the questions or inquiry and, as appropriate, provide clarification or other notes on the Study subject’s CRF within 5 working days. 

  

	 	4.5.4	 The Study Site shall deliver all paper Study CRFs (if and as applicable) to Sponsor or the CRO, as applicable,
within 30 calendar days after the last Study visit of the last Study subject and after Study source data verification by the monitor, or – without limiting the foregoing – the date on which Sponsor or the CRO reasonably request delivery;

  

	 	4.5.5	 Members of the Study Team assigned to the Study, including a deputy investigator as applicable, shall be
authorized by the Investigator, and adequate training and information will be provided to such deputy investigator for such purpose; and 

  

	 	4.5.6	 The Study Site shall archive all Study documentation for 15 years after Study completion (the “Archival
Period”) at the Study Site. This includes a Study subject identification code list, Study subject records including source data, IRB/ethics committee approvals, copies of the Study case report forms, Study subject informed consent forms and
the Investigator site file. Sponsor shall be notified in writing reasonably in advance by the 

  
 Page 3 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

Execution Copy 
  

	 	Study Site of any planned relocation or any other endangerment of the Study documentation within the 10 year retention period. At any time prior to the expiration of the Archival Period, the Sponsor shall provide notice
to the Study Site if it wishes to receive all such Study documentation for archival at a secure location. Sponsor agrees that upon conclusion of its archival of the Study documentation, it will properly destroy all such documentation.

  

	 	4.6	 The Study Site and the Investigator shall promptly reply to any questions raised by Sponsor or the CRO relating
to the Study. The Study Site and Investigator shall promptly notify Sponsor or the CRO of any significant changes that occur during the Study, in particular, changes to the Study Team. 

 

	 	4.7	 Without limiting any other provision of this Agreement, each Investigator for a Study will meet with the Study
Site monitor for such Study in accordance with the Study monitoring schedule and at the Study close-out visit in order to discuss findings, complete paperwork and provide any necessary signatures.

  

	 	4.8	 If the Study Site or the Investigator receives notice that the Study Site and/or a Study shall be subject of an
investigation or inspection related to the Study by any regulatory authority, to the extent permitted by law Study Site and/or Investigator shall notify Sponsor or the CRO immediately. If such Party does not receive prior notice of said
investigation or inspection, to the extent permitted by law the Study Site or the Investigator shall inform Sponsor or the CRO as soon as possible after receiving knowledge of said investigation or inspection. 

 

	5.	 Reporting of Serious Adverse Events 

If a Serious Adverse Event (“SAE”) occurs during any Study, it shall be reported without undue delay (i.e., within 1 business day after
Study Site becomes aware of such SAE) to the designated pharmacovigilance unit at the CRO or at Sponsor or at any other third party designated by Sponsor and identified to Study Site. The Study Site shall answer any possible questions relevant to
such SAE to its best knowledge. 
  

	6.	 Investigational Drug Product 

Sponsor, or a third party designated by Sponsor, shall provide the Study Site and the Investigator free of charge with a sufficient amount of Investigational
Drug Product (“IDP”) for the treatment of Study subjects at Study Site, to cover the planned administration of the IDP according to the Study Protocol. The IDP provided hereunder shall exclusively be used for purposes of the
applicable Study. 
 The Study Site and the Investigator shall ensure that the IDP shall be stored, prepared and administered adequately in accordance with
the Study Protocol, the Investigator’s Brochure, ICH-GCP guidelines and any applicable laws. Any partially used and/or unused IDP shall be returned to Sponsor or a third party designated by Sponsor or, if
local laws and regulations permit, at the request of Sponsor shall be destroyed at the Study Site. The Study Site shall diligently account for and appropriately document any of such activities (storage, preparation, administration,
return/destruction) and shall allow Sponsor the inspection of such documentation. 

  
 Page 4 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

Execution Copy 
  

	7.	 Responsibilities of Sponsor 

Sponsor and CRO shall conduct monitoring visits in accordance with the Study Protocol, ICH-GCP Guidelines and
applicable laws. Sponsor shall provide the Study Site with all IDP required for the conduct of this Study free of charge. Fees charged by the Study Site’s IRB shall be covered by Sponsor. Sponsor shall enter into an insurance policy that
provides coverage for all potential damages or injuries to Study subjects arising from participation in the Study and shall provided Study Site with written evidence of such insurance. 

 

	8.	 Liability / Indemnification 

 

	 	8.1	 Sponsor shall indemnify the Study Site and Investigator, System, and their Regents, employees, officers, and
agents from compensation requests from patients, their legal representatives or legal successors following health damages, death or financial losses in as far as such were caused by the IDP and Study related procedures; save where such compensation
requests arise as a consequence of Study Site and/or Investigator willful acts or omission and/or negligence. 

  

	 	8.2	 To the extent authorized by the constitution and laws of the State of Texas, the Study Site shall indemnify
Sponsor from compensation requests from patients, their legal representatives or legal successors following Study related health damages, death or financial losses in as far as they are a consequence of Study Site’s and/or Investigator’s
willful acts or omission and/or negligence in conduct of the Study. 

  

	9.	 Ownership and Publication of Data 

Sponsor shall be the sole and exclusive owner of all data generated over the course of each Study conducted at the Study Site (the “Data”).
The Study Site and Investigator shall have the right to use Data for internal research, academic, and patient care purposes prior to publication or public disclosure, and for any purpose after such publication or public disclosure. Study Site
(and/or Investigator if authorized by Study Site) will have the right to publish Data, either in writing or orally (both being a “Publication”), provided that Study Site, will provide Sponsor with notice of any such proposed
Publication at least thirty (30) days prior to date of or submission for Publication. Within such thirty (30) day period, Sponsor will review such proposed Publication for any Confidential Information of Sponsor and provide written notice
to Study Site or Investigator, as applicable, if Sponsor believes that such Publication contains such Confidential Information. If Sponsor fails to provide written notice within such thirty (30) day period, such proposed Publication shall be
deemed to not contain any Confidential Information. Study Site and/or Investigator will remove Confidential Information of Sponsor that has been so identified. 
  

	10.	 Confidentiality 

Subject to Section 9, the Study Site and the Investigator shall treat as confidential all information received from Sponsor or the CRO in connection with
the Study or information developed in the course of the Study (the “Confidential Information”) and shall not disclose any of this to any third party unless such information: (a) is published or otherwise publicly available at
the time of disclosure to Study Site or Investigator; (b) otherwise becomes publicly available by a third party; (c) is independently developed by Study Site or Investigator without use of Sponsor Confidential Information; (d) is
required to be disclosed pursuant to applicable law or regulation. The Study Site shall impose such confidentiality obligations on its employees to whom the Study has been entrusted as well as on third parties which were engaged by Study Site in
order to fulfill Study Site’s obligations under this Agreement. The obligations of confidentiality of this Section 10 shall remain in effect for a period of 5 years after expiration or termination

  
 Page 5 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

Execution Copy 
  

of this Agreement except as to the Investigator’s Brochure for a Study, and the Study Protocol, with respect to which the obligations of confidentiality
of this Section 10 shall remain in effect for a period of 10 years after expiration or termination of this Agreement, provided that such obligations of confidentiality shall not apply to the extent that any information contained therein does
not otherwise fall within the definition of Confidential Information or is subject to any exception under this Section 10. 
  

	11.	 Debarment 

The Study Site represents and certifies that neither the Investigator nor the Study Site have been, or are currently, an individual, corporation, partnership,
association or entity that has been debarred by the applicable regulatory authorities. The Study Site further represents and certifies that it has no knowledge of any circumstances which may affect the accuracy of the foregoing representations and
certifications, including, but not limited to, regulatory investigations of, or debarment proceedings against, the Study Site or any other person or entity performing services or rendering assistance relating to any Study. The Study Site and the
Investigator shall immediately notify Sponsor or the CRO if they become aware of any such circumstances at any time. 
  

	12.	 Payment / Remuneration 

Sponsor shall compensate Study Site for the work performed under each Study pursuant to the terms set forth in Article 4 of the Collaboration Agreement
(Research Support) and the approved Work Order. To the extent that the “discounted” pricing set forth in Exhibit C of the Collaboration Agreement is different from the pricing agreed to by the Parties in an approved Work Order, the Work
Order pricing will control. Each Work Order shall further specify the schedule for any payments and the amounts applicable to the Study. The Investigator shall not personally receive any remuneration by Sponsor under this Agreement. 

 

	13.	 Termination 

  

	 	13.1	 This Agreement comes into effect as of the Effective Date and shall terminate as of termination or conclusion
of the last Study. 

  

	 	13.2	 Sponsor has the right to terminate a Study by declaration of Sponsor at any time for medical and/or
administrative reasons. Any termination under this Agreement has to be in writing. 

  

	 	13.3	 The Study Site may terminate its Study participation at any time in writing in a Study, in case it reasonably
believes that Study subjects are in any way at an unacceptable risk. Sponsor shall promptly be notified in writing of such fact. 

  

	14.	 Contact person 

Sponsor and Study Site shall each appoint and, if necessary, re-appoint a contact person. The person initially
appointed by Sponsor is [***] and the person initially appointed by the Study Site is [***] 
  

	15.	 Miscellaneous 

 

	 	15.1	 Any modifications or amendments and additions to this Agreement shall be made in writing to be valid.

  
 Page 6 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

Execution Copy 
  

	 	15.2	 Any disputes or claims arising under this Agreement will be governed by the laws of the State of Texas and the
venue will be the state and/or federal judicial courts in Harris County, Texas. 

  

	 	15.3	 The parties are independent contractors and this Agreement does not create a joint venture, partnership,
employment, agency or any other similar relationship. 

  

	 	15.4	 If one or more of the provisions of this Agreement are or become legally invalid this shall not affect the
validity of the remaining provisions. The invalid provision shall be replaced as soon as possible by another provision which reflects as closely as possible the sense and purpose of the invalid provision. The same shall apply in the event of a gap
in this Agreement or should a provision of this Agreement be or become ambiguous. 

  

	 	15.5	 All provisions of this Agreement that by their nature and in order to be effective, have to survive, its
termination, including but not limited to Sections 4, 5, 7, 8, 9 and 10, shall survive such termination. 

  

	 	15.6	 Study Site is an agency of the State of Texas and is subject to the constitution and laws of the State of
Texas. Nothing in this Agreement shall constitute or be construed as a waiver of the sovereign immunity of the State of Texas or a waiver, restriction, or limitation of any right of the State of Texas. 

[signatures follow on next page] 
 In
witness whereof, the Parties hereto have caused this Agreement to be executed by their duly authorized representatives to be effective as of the Effective Date. 
  

 
  

									
	 The University of Texas MD Anderson Cancer

Center
	 		 	Immatics US, Inc.
					
	Date:	 	 12/8/16
	 		 	Date:	 	 12/12/2016

			
	 /s/ Wesley Harrott
	 		 	 /s/ Harpreet Singh

	Name: Wesley Harrott	 		 		 	Name: Harpreet Singh
	 Function: Associate Vice President 

                Research Administration
	 		 		 	  Function: President & CEO

  
 Page 7 

 Exhibit A 

EXAMPLE WORK ORDER No. __ 
 This Work
Order (“Work Order”), effective as of the ___ day of ___ 20__ (“Effective Date”), is entered into by and between The University of Texas MD Anderson Cancer Center, with a place of business located at 1515 Holcombe Blvd.,
Houston, TX 77030, USA (“Study Site”), a member institution of The University of Texas System (“System”) and Immatics US, Inc., having a principal place of business at 2130 Holcombe, Suite 11.3000, Houston, Texas
(“Sponsor”) (Study Site and Sponsor each a “Party” and collectively the “Parties”). This Work Order is a part of, and is subject to, the terms and conditions of the Master Clinical 

Trial Agreement entered into between Study Site and Sponsor dated October ___ 2016 (the “Agreement”). 

 

	1.	 The Parties enter into this Work Order in connection with the Study entitled: ___________________, to be
conducted pursuant to Protocol No. __________, as attached hereto and incorporated herein. 

  

	2.	 __________ is the Investigator (as defined in the Agreement) for the Study which will be conducted at Study
Site. 

  

	3.	 The Investigational Drug Product (“IDP”) for the above referenced Study is _____.

  

	4.	 The Study Budget is ___________ ($______.___) and shall be payable in accordance with the terms set forth in
the Collaboration Agreement, unless expressly modified herein. 

  

	5.	 Specific superseding terms: _____________. 

In witness whereof, the Parties hereto have caused this Work Order to be executed by their duly authorized representatives to be effective as of the
Effective Date. 
  

									
	 The University of Texas

MD Anderson Cancer Center
	 	Immatics US, Inc.
					
	Date:	 	  
	 		 	Date:	 	  

			
	             
	 		 	
                

	Name:	 		 	Name:	 	
	Function:	 		 	Function:	 	

 READ AND UNDERSTOOD: 

I confirm that I have received a copy of the Agreement under which this Work Order is issued, and that I have read and understand the Agreement and this Work
Order. I further agree to ensure that any subinvestigators and research staff and all collaborating physicians who are assisting in the conduct of the Study are informed of their obligations under the Agreement and this Work Order.  

Principal Investigator 
 Date:
_____________________________________________ 
 __________________________________________________ 

NameEX-10.8

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

Exhibit 10.8 
 Execution
Version 
 IMMATICS US, INC. 

RESTRICTED STOCK ACQUISITION AGREEMENT 

THIS RESTRICTED STOCK PURCHASE AGREEMENT (the
“Agreement”) is made as of the 14th day of August, 2015, by and among IMMATICS US, INC., a Delaware corporation (the
“Company”), the Board of Regents of the University of Texas System, for the benefit of the University of Texas M.D. Anderson Cancer Center, a member institution of The University of Texas System and an agency of the State of
Texas (“MD Anderson”), and IMMATICS BIOTECHNOLOGIES GMBH (the “Parent”) (solely with respect to terms and conditions set forth under
Sections 1(d), 2, 5, 9 and 10). 
 WHEREAS, the Company desires to issue, and MD
Anderson desires to acquire, stock of the Company as herein described, on the terms and conditions hereinafter set forth. 

NOW, THEREFORE, IT IS
AGREED between the parties as follows: 
  

	1.	 ISSUANCE OF INITIAL
SHARES; PURCHASE RIGHT. 

(a)    Issuance of Initial Shares. Subject to Section 1(f), MD Anderson hereby agrees to acquire
from the Company, and the Company hereby agrees to issue to MD Anderson, an aggregate of [***] shares (the “Initial Shares”) of the common stock of the Company, with [***] par value per share (the “Common
Stock”), with an aggregate value of [***] in partial consideration of services rendered and to be rendered by MD Anderson to the Company pursuant to the terms of that certain Collaboration & License Agreement, dated as of the
date hereof, by and between the Company and MD Anderson (the “Collaboration Agreement”). The issuance of the Initial Shares hereunder (the “Initial Closing”) shall occur at the offices of the Company
immediately following the execution of this Agreement or at such other time and place as the parties may mutually agree. Upon execution of this Agreement, and subject to Section 1(f), the Company shall issue one stock certificate per Initial
Milestone set forth on Exhibit A-1, such that each stock certificate represents a number of Initial Shares equal to the dollar amount of such Initial Milestone as set forth on Exhibit A-1 divided by [***] (“Initial Per Share Stock Price”) 

(b)    Purchase Right. Subject to Section 1(e), in the event that any performance milestone set forth
on Exhibit A-1 attached hereto and as amended after the date hereof, including based on the process outlined in the Collaboration Agreement (each, an “Initial Milestone”,
collectively, the “Initial Milestones” and, together with the Subsequent Milestones, the “Milestones”) is not completed (“Uncompleted Initial Milestones”), as of the Initial
Determination Date (as defined below), by MD Anderson in a satisfactory manner, as determined by the Company’s Board of Directors in good faith and in its reasonable discretion after good faith discussion of the JSC as set forth in the
Collaboration Agreement and, if necessary, after completion of the dispute resolution process under the Collaboration Agreement (the completion of such standard constituting “Satisfactory Performance” and with respect to
describing the state of a Milestone, being “Satisfactorily Performed”), the Company shall purchase from MD Anderson, and MD Anderson shall be required to sell to the Company such number of Initial Shares equal to the product
obtained by multiplying: (a) the aggregate number of Initial Shares; by (b) a fraction, the numerator of which is the aggregate dollar value, as set forth on Exhibit A-1 attached
hereto, of the Uncompleted Initial Milestones as of the Initial Determination Date (as defined below), and the denominator of which is [***] (the “Purchase Right” and the Initial Shares subject thereto, the
“Purchase Shares”), at a price per share equal to [***] (the “Purchase Price”). The “Initial Determination Date” shall be the earlier of: (i) the date on which the
Collaboration Agreement is terminated, pursuant to its terms, for any reason; and (ii) the earlier of (x) three (3) years following the date hereof and (y) the expiration of the Research Term (as such term is defined in the
Collaboration Agreement). For the avoidance of doubt and subject to Section 1(f): (A) following the Satisfactory Performance by MD Anderson of any 

  
 1 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

Initial Milestone, the Initial Shares attributable to the value of such Initial Milestone as set forth on Exhibit
A-1 (with respect to each Initial Milestone, the “Initial Milestone Dollar Value”) shall be released from, and shall no longer be subject to the Purchase Right, and shall be
delivered to MD Anderson as soon as possible after the Satisfactory Performance of the applicable Initial Milestone; (B) following the Satisfactory Performance by MD Anderson of all of the Initial Milestones, the unreleased Initial Shares shall
be released from, and shall no longer be subject to, the Purchase Right; and (C) any Initial Shares attributable to the Access Fee as set forth in Exhibit A-1 shall not be subject to the
Purchase Right and the share certificate representing such Initial Shares attributable to the Access Fee shall be delivered to MD Anderson upon the parties’ execution and delivery of this Agreement. Notwithstanding anything contained herein to
the contrary, in the event that MD Anderson has materially begun performance of a specific Initial Milestone as of the date on which the Collaboration Agreement is terminated in accordance with its terms, and provided that the Collaboration
Agreement is not terminated as a result of a breach of the Collaboration Agreement by MD Anderson (any such Initial Milestone, a “Partially Performed Initial Milestone”), then in exchange for a cash payment by the Company to
MD Anderson equal to the entire aggregate dollar value, as set forth on Exhibit A-1 attached hereto, of such Partially Performed Initial Milestone, any such Partially Performed Initial Milestone
shall be deemed to be an Uncompleted Initial Milestone (and shall be subject to the Purchase Right). 

(c)    Exercise of Purchase Right. In the event that the Company has the right to purchase all or any
portion of the Initial Shares pursuant to the Purchase Right described in Section 1(b), the Company shall be deemed to have exercised the Purchase Right as to the Purchase Shares effective as of the Initial Determination Date, and the purchase
of the Purchase Shares by the Company shall be deemed effective immediately. The Company shall provide written notice of the purchase of the Purchase Shares to MD Anderson as soon as practicable following the Initial Determination Date. On the
Initial Determination Date, the Company shall become the legal and beneficial owner of all of the Purchase Shares purchased pursuant to the Purchase Right and all rights and interest therein or related thereto, and the Company shall have the right
to transfer to its own name all such Purchase Shares without further action by MD Anderson. Following the Initial Determination Date, the Company shall pay for any Purchase Shares purchased pursuant to the Purchase Right at the Company’s option
in cash or by offset against any undisputed indebtedness owing to the Company by MD Anderson. 

(d)    Adjustment to Initial Shares. If, from time to time, prior to the Initial Determination Date,
and subject in all cases to Section 1(e), there is any change affecting the Company’s outstanding Common Stock as a class that is effected without the receipt of consideration by the Company (through merger, consolidation, reorganization,
reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, change in corporation structure or other transaction), then any and all new, substituted or additional securities or
other property to which MD Anderson is entitled by reason of MD Anderson’s ownership of the Initial Shares shall be immediately subject to the Purchase Right and be included in the word “Initial Shares” for all purposes of this
Agreement, with the same force and effect as the Initial Shares presently subject to this Agreement. For the avoidance of doubt, while the total Purchase Price shall remain the same after each such event, the Purchase Price per Purchase Share upon
exercise of the Purchase Right shall be appropriately adjusted. In addition, in connection with any exercise of the Put Option or the Call Option (each as defined in Exhibit C), the Transfer Documents (as defined in Exhibit
C) shall include provisions pursuant to which the shares of Parent Common Stock issuable to MD Anderson in exchange for the Initial Shares shall be subject to the Purchase Right and be included in the words “Initial Shares” for all
purposes of this Agreement, provided that Parent or one or more third parties nominated by Parent shall be entitled to exercise the Purchase Right. For the avoidance of doubt, while the total Purchase Price shall remain the same with respect to the
Parent Common Stock after exercise of the Put Option or Call Option, the Purchase Price per share of Parent Common Stock upon exercise of the Purchase Right shall be appropriately adjusted to provide an equitable result. In addition, the Initial Per
Share Stock Price may be adjusted in the event there is a change affecting the Company’s outstanding Common Stock as a class that is effected without the receipt of consideration by the Company (through merger, consolidation, reorganization,

  
 2 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

reincorporation, stock dividend, dividend in property other than cash, stock split, liquidating dividend, combination of shares, change in corporation
structure or other transaction). For example, if there is a 5 to 1 reverse stock split, then the Initial Per Share Stock Price shall be proportionately increased. 

(e)    Corporate Transaction. In the event that: (i) an Acquisition (as defined below); or (ii) an
Asset Transfer (as defined below) ((i) and (ii) being collectively referred to herein as a “Corporate Transaction”) occurs before the Initial Determination Date, notwithstanding any provision of this Agreement to the
contrary other than Section 1(f), all of the previously unvested Initial Shares shall become immediately vested and shall no longer be subject to the Purchase Right. The parties shall use their reasonable best efforts to cause such acceleration
of the vesting of Shares to occur in a manner and at a time which allows MD Anderson the ability to participate in the Corporate Transaction with respect to its Shares. For the purposes of this Section 1(e): (i)
“Acquisition” shall mean: (A) any consolidation or merger of the Company with or into any other Person, or any other corporate reorganization; or (B) any transaction or series of related transactions to which the
Company is a party in which in excess of fifty percent (50%) of the Company’s then issued and outstanding voting power is transferred; or (C) the closing of a public offering of Company stock on a nationally recognized stock exchange; and
(ii) “Asset Transfer” shall mean a sale, lease, exclusive license or other disposition of all or substantially all of the assets of the Company. Notwithstanding any acceleration of vesting in accordance with this
Section 1(e), nothing herein shall relieve, or be deemed to relieve, MD Anderson of its obligations to render services and otherwise perform in accordance with the Collaboration Agreement following the consummation of any Corporate Transaction
prior to the termination or expiration of such Collaboration Agreement. 
 (f)    Credit for FF&E
Payments. 
 (i)    The Company may sublease office, laboratory, and storage space located in Houston, Texas,
from MD Anderson or one of its affiliates pursuant to a written agreement (the “Sublease Agreement”). Any Sublease Agreement shall set forth, among other payment obligations, the monthly amounts payable by Company that are
allocable to Company’s use of MD Anderson’s furniture, fixtures and equipment within the subleased space (the “FF&E Payment”). The parties agree that the dollar amounts of the FF&E Payments, stated on a per
calendar month basis will accumulate during the term of the Sublease Agreement and be credited back to the Company at each time an Initial Milestone has been Satisfactorily Performed, in accordance with the terms and conditions set forth in this
Section 1(f), and/or upon achievement of Completed Subsequent Milestones in accordance with Section 2(c). 

(ii)    As the FF&E Payments are paid, the Company will maintain records that reflect the amount of such
payments that have been made after the effective date of the Sublease Agreement, as reduced or increased from time to time in accordance with this Section 1(f) and/or Section 2(c) (as determined at any given point in time, the
“Cumulative FF&E Payments”). 
 (iii)    Within three (3) days after either an
Initial Milestone has been Satisfactorily Performed by MD Anderson and/or after delivery of a Put Election Notice or a Call Election Notice in accordance with Exhibit C and/or upon consummation of a Corporate Transaction, the parties shall determine
the remaining amount of the Cumulative FF&E Payments that are available to credit, based upon the following formula (with respect to Initial Shares as determined at any given point in time and, with respect to Milestone Shares, determined as of
the Subsequent Closing, the “Net Cumulative FF&E Payments”): The Cumulative FF&E Payments that have been paid by the Company to MD Anderson prior to the date on which such Initial Milestone has been Satisfactorily
Performed (or the date of delivery of a Put Election Notice or Call Election Notice or the date on which a Corporate Transaction is consummated), less any Cumulative FF&E Payments that had been previously credited against the amount of an
Initial Milestone in accordance with this Section 1(f) or credited against the amount of the Completed Subsequent Milestones in accordance with Section 2(c). 

  
 3 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

(iv)    In addition, the parties shall calculate the number of Initial Shares that would have to be returned to the
Company or that are no longer subject to the Purchase Right of the Company and delivered to MD Anderson based on the following formula, as determined as of the date the Initial Milestone in issue was Satisfactorily Performed (or the date of delivery
of a Put Election Notice or Call Election Notice or the date on which a Corporate Transaction is consummated): 
 the amount of the Initial
Milestone Dollar Value with respect to the Initial Milestone that has been Satisfactorily Performed (or the Initial Milestones applicable to Initial Shares for which vesting is to be accelerated in connection with the delivery of a Put Election
Notice or Call Election Notice or in accordance with Section 1(e)) less the Net Cumulative FF&E Lease Payments (the difference being referred to as the “Initial Milestone Difference”). 

(A)    If the Initial Milestone Difference is a positive number (the “Initial Milestone Positive
Difference”), then the Company shall receive a credit for the full amount of the Net Cumulative FF&E Payments made by Company (determined as of such date), and the Company shall deliver a stock certificate representing the number of
Initial Shares determined as follows: (I) the amount of the Initial Milestone Positive Difference, divided by (II) the Current Per Share Stock Price per share of common stock of the Company; and 

(B)    If the Initial Milestone Difference is a negative number (the “Initial Milestone Negative
Difference”), then the Company shall receive a credit against the Initial Milestone Dollar Value for such Initial Milestone in the full amount of the Net Cumulative FF&E Payments made by Company (determined as of such date), and MD
Anderson shall not be entitled to obtain any Initial Shares with respect to such Initial Milestone that had been Satisfactorily Performed (or the Initial Milestones applicable to Initial Shares for which vesting is to be accelerated in connection
with the delivery of a Put Election Notice or Call Election Notice or in accordance with Section 1(e)). In addition the amount of the Initial Milestone Negative Difference (stated as an absolute number) shall be considered outstanding and
included as part of the Net Cumulative FF&E Payments with respect to Initial Milestones and/or Completed Subsequent Milestones becoming Satisfactorily Performed in the future. 

(v)    Notwithstanding anything to the contrary contained herein, the Company shall not have the ability to credit
the Net Cumulative FF&E Payments against the Access Fee shares. Also, for the avoidance of doubt, with respect to Initial Shares for which an Initial Milestone Difference has previously been determined and for which an adjustment has been made
(in each case in accordance with Section 1(f)(iv)), the Company shall not have the ability to credit Cumulative FF&E Payments that accrue after the date used to determine the Net Cumulative FF&E Payments with respect to such Initial
Shares that have been issued in accordance with Section 1(f)(iii). For further clarity, (A) each Initial Share issuance shall only be subject to a single adjustment for certain FF&E Payments as set forth in
Section 1(f), (B) and, once such single adjustment has been made, the Initial Shares issued will not be subject to further adjustment/reduction based on FF&E Payments accruing in the future, and (C) after a Parent Exit Event, there
will be no adjustment for FF&E Payments set forth in Section 1(f) with respect to the Initial Shares. 

(vi)    For illustration purposes only, assume that (A) the FF&E Payment was [***] per month, (B) the
first Initial Milestone was Satisfactorily Performed by MD Anderson on November 1, 2015, (C) the Initial Milestone Dollar Value for such Initial Milestone on Exhibit A-1 was [***], (D) the Net
Cumulative FF&E Payment prior to November 1, 2015 was [***] (4 months at [***] per month). In this case, when the Initial Milestone was Satisfactorily Performed, the parties would determine the Initial Milestone Dollar Value as set forth on
Exhibit A-1, which would be [***]. Subtract the amount of the Net Cumulative FF&E Payments, [***], from [***], to determine the Initial Milestone Positive Difference [***]. MD Anderson would be entitled to
the number of Initial Shares equal to the following amount based upon the following formula: 
 [***] 

  
 4 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

(g)    Termination of Purchase Right. Sections 1(b)-1(f) of
this Agreement shall terminate upon the exercise in full or expiration of the Purchase Right, whichever occurs first; provided, however, that Section 1(f) shall not terminate with respect to Completed Subsequent Milestones and
Section 2(c). 
 (h)    Escrow of Unvested Initial Shares. Subject to Section 1(i), security for
MD Anderson’s performance of the terms of this Agreement and to insure the availability for delivery of MD Anderson’s Purchase Shares upon exercise of the Purchase Right herein provided for, MD Anderson agrees that the Secretary of
the Company or the Secretary’s designee, acting as an escrow agent (the “Escrow Agent”), shall hold the Initial Shares that have not yet vested in accordance with Section 1(b) in escrow until the earlier of
(i) the Initial Determination Date and (2) a Corporate Transaction. In the event of any purchase by the Company (or any of its assigns), MD Anderson shall date, complete, and execute a stock assignment substantially in the form attached
hereto as Exhibit B as necessary for the transfer of the Initial Shares being purchased and to transfer such shares in accordance with the terms of this Agreement. If any Initial Shares are not purchased by the Company in accordance
with Section 1 hereof, the Escrow Agent shall release to MD Anderson the stock certificate(s) representing such Initial Shares. MD Anderson hereby acknowledges and agrees that the Secretary of the Company, or the Secretary’s designee, is
so appointed as the Escrow Agent, with the foregoing authorities as a material inducement to make this Agreement and that said appointment is coupled with an interest and is accordingly irrevocable. The Company shall be solely responsible for any
fees or expenses of the Escrow Agent. The Escrow Agent may rely upon any letter, notice or other document executed by any signature purported to be genuine and may resign at any time. MD Anderson agrees that if the Secretary of the Company, or the
Secretary’s designee, resigns as the Escrow Agent for any or no reason, the Board of Directors of the Company shall have the power in its sole discretion to appoint a successor to serve as the Escrow Agent pursuant to the terms of this
Agreement. MD Anderson agrees that if the Secretary of the Company, or the Secretary’s designee, resigns as Secretary, the successor Secretary shall serve as the Escrow Agent pursuant to the terms of this Agreement. 

(i)    Rights of MD Anderson. Subject to the provisions of Sections 1(h), 2, 3, 4, 5 and 11 herein, MD
Anderson shall exercise all rights and privileges of a stockholder of the Company with respect to the Initial Shares deposited in escrow. MD Anderson shall be deemed to be the holder for purposes of receiving any dividends that may be paid with
respect to such Initial Shares and for the purpose of exercising any voting rights relating to such Initial Shares, even if some or all of such Initial Shares are unvested, or have not been released from escrow, or have not yet been released from
the Purchase Right. Any notices or other communications provided to stockholders of the Company shall be provided to MD Anderson at the same time that such communication is provided to the stockholders of the Company, and shall be deemed ineffective
if given to the Escrow Agent. 
  

	2.	 ISSUANCE OF MILESTONE SHARES AND
SHARES UNDER LICENSE AGREEMENT. 

(a)    After the Initial Closing, in partial consideration of services rendered by MD Anderson to the Company
pursuant to the terms of the Collaboration Agreement, the Company shall, on the same terms and conditions as those contained in this Agreement, issue to MD Anderson such number of additional shares of Common Stock (the
“Milestone Shares”) equal to the quotient obtained by dividing: (a) the aggregate dollar value, as set forth on Exhibit A-2 attached hereto, as the same
may be adjusted in accordance with Section 2(c), of the Completed Subsequent Milestones (as defined below); by (b) the fair market value of the Common Stock, as determined in good faith by the Company’s Board of Directors (taking into
account, among other things, the strike price of any recent grants of stock options to employees, consultants or directors of the Company, or any 409A valuation 

  
 5 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

completed with respect to the fair market value of the Company’s Common Stock) (the “Subsequent Milestone Per Share Price”), as of
the earlier of: (i) the date on which all of the Subsequent Milestones (as defined below) have been Satisfactorily Performed by MD Anderson; (ii) the date on which the Company has notified MD Anderson that the Company will not request MD
Anderson to initiate work on any outstanding Subsequent Milestone(s); (iii) the date on which the Collaboration Agreement is terminated, pursuant to its terms, for any reason; and (iv) four (4) years following the date hereof (such date, the
“Subsequent Determination Date”). The issuance of the Milestone Shares hereunder (the “Subsequent Closing” and, together with the Initial Closing, each a “Closing”) shall occur
at the offices of the Company within thirty (30) days following the Subsequent Determination Date. The “Subsequent Milestones” shall be those performance milestones set forth on Exhibit A-2 attached hereto, and as amended after the date hereof, including based on the process outlined in the Collaboration Agreement, and the “Completed Subsequent Milestones” shall be
those Subsequent Milestones which have been Satisfactorily Performed by MD Anderson as of the Subsequent Determination Date. Notwithstanding anything contained herein to the contrary, in the event that MD Anderson has materially begun performance of
a specific Subsequent Milestone as of the date on which the Collaboration Agreement is terminated, and provided that the Collaboration Agreement is not terminated as a result of a material breach of the Collaboration Agreement by MD Anderson that
remains uncured (any such Subsequent Milestone, a “Partially Performed Subsequent Milestone”), then in exchange for a cash payment by the Company to MD Anderson equal to the aggregate dollar value, as set forth on
Exhibit A-2 attached hereto, of such Partially Performed Subsequent Milestone, any such Partially Performed Subsequent Milestone shall be deemed not to be a Completed Subsequent Milestone. In
connection with the exercise of the Put Option or the Call Option (each as defined in Exhibit C), the Transfer Documents (as defined in Exhibit C) shall include provisions pursuant to which shares of Parent Common Stock
shall be issued following the Subsequent Determination Date to MD Anderson as Milestone Shares (in lieu of shares of Common Stock of the Company), with such number of shares of Parent Common Stock determined in accordance with the terms of this
Section 2 and of Exhibit C. 
 (b)    Pursuant to the License Agreement for MDA[***] (i.e.
Gamma Delta T cells) simultaneously executed with this Agreement by and between MD Anderson and the Company (the “License Agreement”), the Company may issue shares of Common Stock to MD Anderson in lieu of cash (the
“License Agreement Shares” and, together with the Initial Shares and the Milestone Shares, the “Shares”). If any License Agreement Shares are issued to MD Anderson, such License Agreement Shares
(i) shall be fully vested upon issuance and shall not be subject to the Purchase Right, and (ii) shall have the same rights and obligations as the capital stock of the Company, issued pursuant to this Agreement, including, without
limitation, the rights and obligations set forth in Sections 5, 6 and 9. 
 (c)    If the parties enter into the
Sublease Agreement, the parties may agree that the FF&E Payments may accumulate during the term of the Sublease Agreement and be credited back to the Company at each time an Initial Milestone has been Satisfactorily Performed, in accordance with
the terms and conditions set forth in Section 1(f), and/or upon achievement of Completed Subsequent Milestones in accordance with this Section 2(c).  

(i)    No later than three (3) days prior to the Subsequent Closing, the parties shall determine the remaining
Net Cumulative FF&E Payments. 
 (ii)    In addition, the parties shall calculate the number of Milestone
Shares to be issued to MD Anderson based on the following formula, as determined as of the date of the Subsequent Closing: 
 the aggregate
dollar value, as set forth on Exhibit A-2 attached hereto of the Completed Subsequent Milestones less the Net Cumulative FF&E Payments (the difference being referred to as the
“Subsequent Milestone Difference”). 

  
 6 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

(A)    If the Subsequent Milestone Difference is a positive number (the “Subsequent Milestone Positive
Difference”), then the Company shall receive a credit for the full amount of the Net Cumulative FF&E Payments made by Company (determined as of the date of the Subsequent Closing), and the Company shall deliver a stock certificate
representing the number of Milestone Shares determined as follows: (I) the amount of the Subsequent Milestone Positive Difference, divided by (II) the Subsequent Milestone Per Share Price; and 

(B)    If the Subsequent Milestone Difference is a negative number (the “Subsequent Milestone Negative
Difference”), then the Company shall receive a credit against the aggregate dollar value, as set forth on Exhibit A-2 attached hereto, of the Completed Subsequent Milestones in the
full amount of the Net Cumulative FF&E Payments made by Company (determined as of the date of the Subsequent Closing), and MD Anderson shall not be entitled to obtain any Milestone Shares with respect to such Completed Subsequent Milestones. In
addition the amount of the Subsequent Milestone Negative Difference (stated as an absolute number) shall be considered outstanding and included as part of the Net Cumulative FF&E Payments with respect to Initial Milestones becoming
Satisfactorily Performed in the future. 
 (iii)    For the avoidance of doubt, with respect to Milestone Shares
for which an Subsequent Milestone Difference has previously been determined and for which an adjustment has been made (in each case in accordance with Section 2(c)), the Company shall not have the ability to credit Cumulative FF&E Payments
that accrue after the date used to determine the Net Cumulative FF&E Payments with respect to such Milestone Shares in accordance with Section 2(c)(i). 

3.      LIMITATIONS ON TRANSFER. In addition to any other limitation
on transfer created by applicable securities Laws, MD Anderson shall not assign, hypothecate, donate, encumber or otherwise dispose of any interest in the Initial Shares while such Initial Shares are subject to the Purchase Right. After any Initial
Shares have been released from the Purchase Right, MD Anderson shall not assign, hypothecate, donate, encumber or otherwise dispose of any interest in such Initial Shares except in compliance with the provisions herein and applicable securities
Laws. Notwithstanding the foregoing, MD Anderson shall not be subject to the limitations on transfer set forth in this Section 3 with respect to Initial Shares that MD Anderson is required to place in blind trust, or is otherwise required to
transfer in order to comply with applicable Laws or any bona fide requirement of The University of Texas System that MD Anderson discloses to the Company within a reasonable period of time after it becomes aware of such requirement; provided,
however, that any such transferee shall agree in the form required by applicable law to become a party to this Agreement and be subject to the terms and conditions hereof as the successor and assignee of MD Anderson. Furthermore, the Shares shall be
subject to any right of first refusal in favor of the Company or its assignees that may be contained in the Company’s Bylaws or any stockholders agreement to which MD Anderson is a party. MD Anderson hereby further acknowledges that MD Anderson
may be required to hold the Shares indefinitely. During the period of time during which the Shares are held by MD Anderson or on behalf of MD Anderson, the value of the Shares may increase or decrease, and any risk associated with such Shares and
such fluctuation in value shall be borne by MD Anderson. 
  

	4.	 RIGHT OF FIRST OFFER. 

(a)    Except as set forth in this Section 4, MD Anderson hereby irrevocably grants to the Company or its
permitted transferees or assigns the right (the “Right of First Offer”), but not the obligation, to purchase all or any portion of any capital stock of the Company (or any interest therein) (the “Transfer
Stock”) that MD Anderson may from time to time propose to assign, sell, offer to sell, pledge, mortgage, hypothecate, encumber, dispose of or otherwise transfer or encumber (a “Proposed Transfer”); provided that
a Proposed Transfer shall not include: (i) any transfer effected pursuant to a Corporate Transaction; or (ii) any transfer effected to the public in an offering pursuant to an effective registration statement filed by the Company under the
Securities Act of 1933, as amended (the “Act”). 

  
 7 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

(b)    Subject to Section 3 hereof, if MD Anderson proposes to make a Proposed Transfer, MD Anderson shall
deliver a written notice (each, a “Proposed Transfer Notice”) to the Company setting forth the terms and conditions of the Proposed Transfer to the Company, with such Proposed Transfer Notice to contain the material terms and
conditions of the Proposed Transfer (including price and form of consideration). To exercise its Right of First Offer, the Company shall deliver within forty-five (45) days after MD Anderson delivers the Proposed Transfer Notice to the Company
a written notice (each, a “Company Notice”) to MD Anderson notifying MD Anderson that the Company intends to exercise its Right of First Offer as to all the Transfer Stock. 

(c)    The closing of the purchase of Transfer Stock by the Company shall take place, and all payments from the
Company shall have been delivered to MD Anderson, by the later of: (i) the date specified in the Proposed Transfer Notice as the intended date of the Proposed Transfer; or (ii) sixty (60) days after delivery of the Proposed Transfer
Notice. 
 (d)    Subject to Section 3 hereof, if Company does not purchase Transfer Stock subject to a
Proposed Transfer Notice from MD Anderson as set forth in Sections 4(a)-4(c), MD Anderson shall have the right to assign, sell, offer to sell, pledge, mortgage, hypothecate, encumber, dispose of or
otherwise transfer or encumber such Transfer Stock in MD Anderson’s discretion, including by transaction with any third party; provided, however, that: (i) any such assignment, sale or other disposition of such Transfer Stock shall be
consummated within one hundred twenty (120) days after delivery of the Proposed Transfer Notice, and shall be on terms that are not more favorable in any material respect to the terms set forth in the Proposed Transfer Notice; and (ii) any
proposed transferee shall agree in the form required by applicable law to become a party to this Agreement and be subject to the terms and conditions hereof as the successor and assignee of MD Anderson. 

(e)    If MD Anderson becomes obligated to sell any capital stock to the Company under this Agreement (including
pursuant to Sections 1, 2, 4 or 9) and fails to deliver such capital stock in accordance with the terms of this Agreement, the Company may, at its option, in addition to all other remedies it may have, send to MD Anderson the purchase price by
certified check or wire transfer to an account designated by MD Anderson for such capital stock of the Company as is herein specified and cancel on its books the certificate or certificates representing the capital stock of the Company to be sold.

 (f)    Any Proposed Transfer not made in compliance with the requirements of this Agreement shall be null and
void ab initio, shall not be recorded on the books of the Company or its transfer agent and shall not be recognized by the Company. 
  

	5.	 DRAG ALONG AND TAG ALONG.

  

	 	(a)	 Drag Along. 

(i)    In the event that the Company’s Board of Directors and the holders of shares of capital stock of the
Company that represent a majority by voting power of all outstanding shares of capital stock of the Company (the “Majority Stockholders”) approve a Corporate Transaction, then MD Anderson hereby agrees with respect to all
shares of capital stock that MD Anderson holds and any other Company securities over which it otherwise exercises dispositive power, including without limitation the Shares: 

(ii)    in the event such Corporate Transaction requires the approval of the stockholders of the Company,
(A) if the matter is to be brought to a vote at a stockholder meeting, after receiving proper notice of any meeting of stockholders of the Company to vote on the approval of such Corporate Transaction, to be present, in person or by proxy, as a
holder of shares of capital stock, at all such meetings and be counted for the purposes of determining the presence of a quorum at such meetings; and (B) to vote (in person, by proxy or by action by written consent, as applicable) all

  
 8 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

shares of capital stock held by (or for the benefit of) MD Anderson in favor of such Corporate Transaction and in opposition of any and all other proposals
that could reasonably be expected to delay or impair the ability of the Company to consummate such Corporate Transaction; 

(iii)    in the event that the Corporate Transaction is to be effected by the sale of shares of capital stock by
the Majority Stockholders (the “Selling Holders”) without the need for stockholder approval, MD Anderson agrees to sell all shares of capital stock beneficially held by MD Anderson (or in the event that the Selling Holders
are selling fewer than all of their shares of capital stock of the Company, shares in the same proportion as the Selling Holders are selling) to the Person to whom the Selling Holders propose to sell their shares of capital stock of the Company;

 (iv)    to refrain from exercising any dissenters’ rights or rights of appraisal under applicable Law at
any time with respect to such Corporate Transaction; 
 (v)    to execute and deliver all related documentation
and take such other action in support of the Corporate Transaction as shall reasonably be requested by the Company; and 

(vi)    not to deposit, and to cause MD Anderson’s affiliates not to deposit, any voting securities owned by
MD Anderson or MD Anderson’s affiliates in a voting trust or subject any such voting securities to any arrangement or agreement with respect to the voting of such shares of capital stock of the Company, unless specifically requested to do so by
the acquiror in connection with a Corporate Transaction. 
 (vii)    Notwithstanding the foregoing, MD Anderson
will not be required to comply with this Section 5(a) in connection with any proposed Corporate Transaction unless: (A) MD Anderson receives with respect to MD Anderson’s shares of a class or series of capital stock consideration per
share that is no less than every other stockholder participating in the transaction with respect to his, her or its shares of the same class or series of capital stock; (B) the proceeds payable to MD Anderson in connection with such transaction
are equal to or greater than the proceeds required to be paid to MD Anderson pursuant to the Company’s Certificate of Incorporation; (C) the maximum liability of MD Anderson in connection with such Corporate Transaction does not exceed the
consideration payable to MD Anderson in such transaction (other than in the case of potential liability for fraud, willful or intentional breach, or willful or intentional misconduct or breach of a representation by MD Anderson relating to MD
Anderson’s title to its securities as to which liability there need not be any such limitation); and (D) the terms of such Corporate Transaction applicable to MD Anderson are materially no less favorable than the terms applicable to each
other stockholder holding the same class or series of shares as MD Anderson. 
  

	 	(b)	 Tag Along. 

(i)    If at any time the Parent and/or its affiliates (collectively, the
“Tag-Along Stockholder,” whether one or more) propose to sell any shares of its capital stock of the Company to any Person who is not an affiliate of such
Tag-Along Stockholder (the “Proposed Transferee”) and the Tag-Along Stockholder cannot or has not elected to exercise its drag-along rights set
forth in Section 5(a), MD Anderson shall be permitted to participate in such sale (a “Tag-Along Sale”) on the terms and conditions set forth in this Section 5(b). 

(ii)    Prior to the consummation of the sale described in Section 5(b)(i), the
Tag-Along Stockholder shall deliver to the Company and MD Anderson a written notice (a “Tag-Along Sale Notice”) of the proposed Tag-Along Sale no more than ten (10) Business Days after the execution and delivery by all the parties thereto of the definitive agreement entered into with respect to the
Tag-Along Sale and, in any event, no later than twenty (20) Business Days prior to the closing date of the Tag-Along Sale. The
Tag-Along Sale Notice shall make reference to MD Anderson’s rights hereunder and shall describe in reasonable detail: (A) the number of shares of capital stock of

  
 9 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

the Company to be sold by the Tag-Along Stockholder; (B) the name of the Proposed Transferee; (C) the per
share purchase price and the other material terms and conditions of the sale, including a description of any non-cash consideration in sufficient detail to permit the valuation thereof; (D) the proposed
date, time and location of the closing of the sale; and (E) a copy of any form of agreement proposed to be executed in connection therewith. 

(iii)    MD Anderson shall exercise its right to participate in a sale of capital stock of the Company by the Tag-Along Stockholder subject to this Section 5(b) by delivering to the Tag-Along Stockholder a written notice (a
“Tag-Along Exercise Notice”) stating its election to do so and specifying the number of shares of capital stock of the Company to be sold by it no later than five (5) Business Days
after receipt of the Tag-Along Sale Notice (the “Tag-Along Period”). The offer of MD Anderson set forth in a
Tag-Along Exercise Notice shall be irrevocable, and, to the extent such offer is accepted, MD Anderson shall be bound and obligated to sell in the proposed sale on the terms and conditions set forth in this
Section 5(b). MD Anderson shall have the right to sell in a sale subject to this Section 5(b) the number of shares of capital stock of the Company equal to the product obtained by multiplying (x) the number of Shares held by or on
behalf of MD Anderson (whether vested or unvested, and including, for the avoidance of doubt, any shares issued under the License Agreement) by (y) a fraction (A) the numerator of which is equal to the number of shares of capital stock of
the Company the Tag-Along Stockholder proposes to sell or transfer to the Proposed Transferee and (B) the denominator of which is equal to the number of shares of capital stock of the Company then owned
by such Tag-Along Stockholder. 
 (iv)    The Tag-Along Stockholder shall use its commercially reasonable efforts to include in the proposed sale to the Proposed Transferee all of the shares of capital stock of the Company that MD Anderson has requested to have
included pursuant to the applicable Tag-Along Exercise Notice, it being understood that the Proposed Transferee shall not be required to purchase shares of capital stock of the Company in excess of the number
set forth in the Tag-Along Sale Notice. In the event the Proposed Transferee elects to purchase less than all of the shares of capital stock of the Company sought to be sold by MD Anderson, the number of
shares to be sold to the Proposed Transferee by the Tag-Along Stockholder and MD Anderson shall be reduced so that each of the Tag-Along Stockholder and MD Anderson is
entitled to sell its Pro Rata Portion of the number of shares of capital stock of the Company the Proposed Transferee elects to purchase (which in no event may be less than the number of shares of capital stock of the Company set forth in the Tag-Along Sale Notice). The term “Pro Rata Portion” means, with respect to the number of shares of capital stock of the Company to be sold by each holder of shares of capital stock of the
Company pursuant to this Section 5(b)(iv), the number of shares of capital stock of the Company equal to the product of (x) the total number of shares of capital stock of the Company the Proposed Transferee proposes to purchase and
(y) a fraction (A) the numerator of which is equal to the number of shares of capital stock of the Company then held by such holder of shares of capital stock of the Company and (B) the denominator of which is equal to the number of
shares then held by all of the holders of shares of capital stock of the Company (including, for the avoidance of doubt, the Tag-Along Stockholder). 

(v)    If MD Anderson does not deliver a Tag-Along Exercise Notice in
compliance with Section 5(b)(iii), it shall be deemed to have waived all of its rights to participate in such sale, and the Tag-Along Stockholder shall thereafter be free to sell to the Proposed
Transferee its shares of capital stock of the Company at a per share price that is no greater than the per share price set forth in the Tag-Along Sale Notice and on other same terms and conditions which are
not materially more favorable to the Tag-Along Stockholder than those set forth in the Tag-Along Sale Notice, without any further obligation to MD Anderson. 

(vi)    If MD Anderson elects to participate in a sale pursuant to this Section 5(b), it shall, subject to the
terms and conditions contained in Section 16(j), (A) receive the same consideration per share after deduction of its proportionate share of the related expenses in accordance with Section 5(b)(vii); (B) make or provide the same
representations, warranties, covenants, indemnities and agreements as the Tag-Along Stockholder makes or provides in connection with the 

  
 10 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

Tag-Along Sale (except that in the case of representations, warranties, covenants, indemnities and agreements
pertaining specifically to the Tag-Along Stockholder, MD Anderson shall make the comparable representations, warranties, covenants, indemnities and agreements pertaining specifically to itself); provided, that
all representations, warranties, covenants and indemnities shall be made by the Tag-Along Stockholder and MD Anderson severally and not jointly and any indemnification obligation in respect of breaches of
representations and warranties that do not relate to MD Anderson shall be in an amount not to exceed the aggregate proceeds received by MD Anderson in connection with any sale consummated pursuant to this Section 5(b); and (C) take all
actions as may be reasonably necessary to consummate the Tag-Along Sale, including, without limitation, entering into agreements and delivering certificates and instruments, in each case, consistent with the
agreements being entered into and the certificates being delivered by the Tag-Along Stockholder. 

(vii)    The fees and expenses of the Tag-Along Stockholder incurred in
connection with a sale under this Section 5(b) and for the benefit of all holders of capital stock of the Company (it being understood that costs incurred by or on behalf of the Tag-Along Stockholder for
its sole benefit will not be considered to be for the benefit of all holders of capital stock of the Company), to the extent not paid or reimbursed by the Company or the Proposed Transferee, shall be shared by all the holders of capital stock of the
Company on a pro rata basis, based on the consideration received by each holder of capital stock of the Company; provided, that no holder of capital stock of the Company shall be obligated to make any out-of-pocket expenditure prior to the consummation of the transaction consummated pursuant to this Section 5(b). 

(viii)    The Tag-Along Stockholder shall have ninety (90) Business
Days following the expiration of the Tag-Along Period in which to sell the shares of capital stock of the Company described in the Tag-Along Sale Notice, on terms not
more favorable to the Tag-Along Stockholder than those set forth in the Tag-Along Sale Notice (which such ninety (90) Business Day period may be extended for a
reasonable time not to exceed 120 Business Days to the extent reasonably necessary to obtain any regulatory approvals). If at the end of such period the Tag-Along Stockholder has not completed such sale, the Tag-Along Stockholder may not then effect a sale of capital stock of the Company subject to this Section 5(b) without again fully complying with the provisions of this Section 5(b). 

(ix)    If the Tag-Along Stockholder sells or otherwise transfers to the
Proposed Transferee any of its shares of capital stock of the Company in breach of this Section 5(b), then MD Anderson shall have the right to sell to the Tag-Along Stockholder, and the Tag-Along Stockholder undertakes to purchase from MD Anderson, the number of shares of capital stock of the Company that MD Anderson would have had the right to sell to the Proposed Transferee pursuant to this
Section 5(b), for a per share amount and form of consideration and upon the terms and conditions on which the Proposed Transferee bought such capital stock of the Company from the Tag-Along Stockholder,
but without indemnity being granted by MD Anderson to the Tag-Along Stockholder; provided, that nothing contained in this Section 5(b) shall preclude MD Anderson from seeking alternative remedies against
such Tag-Along Stockholder as a result of its breach of this Section 5(b). The Tag-Along Stockholder shall also reimburse MD Anderson for any and all reasonable and
documented out-of-pocket fees and expenses, including reasonable legal fees and expenses, incurred pursuant to the exercise or the attempted exercise of the Tag-Along Stockholder’s rights under this Section 5(b)(ix). 

(x)    This Section 5(b) shall not apply to: (A) sales to any employee of the Company; or (B) sales
in a distribution to the public (whether pursuant to a registered public offering, Rule 144 or otherwise). 
  

	6.	 PREEMPTIVE RIGHT. 

(a)    With respect to any issuance or portion thereof (other than an Excluded Issuance, as defined below) by the
Company of shares of Common Stock, securities convertible into Common 

  
 11 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

Stock or other equity securities or rights to acquire such Common Stock or other equity securities (collectively such securities or rights shall be the
“New Securities”), MD Anderson may elect to subscribe for and purchase for the issuance price offered by the Company a portion of such New Securities sufficient to maintain MD Anderson’s Current Ratio (as defined below)
in effect immediately prior to the issuance of the New Securities. 
 (b)    The Secretary of the Company shall
give MD Anderson thirty (30) days written notice before making any sale or offering of New Securities and shall advise MD Anderson of its rights under this Section 6 to participate in such offering. The notice shall describe the price and
the terms on which the Company proposes to sell, transfer, or otherwise sell or distribute such shares of New Securities together with a calculation of MD Anderson’s Current Ratio and the number of shares it would be allowed to purchase under
this Section 6 to maintain MD Anderson’s Current Ratio after such sale was complete. MD Anderson then shall have fifteen (15) days after the date of the notice to advise the Company in writing whether MD Anderson will exercise its
rights hereunder and to deliver payment in full for the shares of New Securities it elects to purchase. If MD Anderson fails to deliver payment for its portion of the New Securities within the requisite time period, the Company shall proceed with
the offering of such New Securities according to the plan described in the notice delivered to MD Anderson and MD Anderson, failing to exercise such rights unless otherwise waived by Parent, shall have no further special purchase rights under this
Section 6 in connection with such offering or any offering of securities thereafter. 

(c)    Notwithstanding any provision hereof to the contrary, in lieu of complying with the provisions of this
Section 6, the Company may elect to give notice to MD Anderson within thirty (30) days after the issuance of New Securities. Such notice shall describe the type, price, and terms of the New Securities. MD Anderson shall have thirty
(30) days from the date notice is given to elect to purchase up to the number of New Securities that would, if purchased by MD Anderson, maintain MD Anderson’s percentage-ownership position, calculated as set forth in Section 6(b)
before giving effect to the issuance of such New Securities. The closing of such sale shall occur within sixty (60) days of the date notice is given to MD Anderson. 

7.      RESTRICTIVE LEGENDS. All certificates representing the Shares shall have
endorsed thereon legends in substantially the following forms (in addition to any other legend which may be required by other agreements between the parties hereto); provided that only certificates representing the Initial Shares shall be endorsed
with a legend in substantially the form of that contained in Section 7(a) below: 
 (a)    “THE SHARES
REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AN OPTION SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE REGISTERED HOLDER, OR SUCH HOLDER’S PREDECESSOR IN INTEREST, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY. ANY
TRANSFER OR ATTEMPTED TRANSFER OF ANY SHARES SUBJECT TO SUCH OPTION IS VOID WITHOUT THE PRIOR EXPRESS WRITTEN CONSENT OF THE COMPANY.” 

(b)    “THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SHARES REPRESENTED BY THIS CERTIFICATE IS SUBJECT
TO, AND IN CERTAIN CASES PROHIBITED BY, THE TERMS AND CONDITIONS OF A CERTAIN RESTRICTED STOCK ACQUISITION AGREEMENT BY AND BETWEEN THE STOCKHOLDER AND THE COMPANY. COPIES OF SUCH AGREEMENT MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF
THE COMPANY.” 
 (c)    “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT
SUCH REGISTRATION IS NOT REQUIRED.” 

  
 12 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

	 	(d)    Any	 legend required by appropriate blue sky officials. 

 

	8.	 REPRESENTATIONS AND WARRANTIES. 

(a)    MD Anderson represents and warrants to the Company that the statements contained in this Section 8(a)
are true and correct as of the date hereof: 
 (i)    MD Anderson is aware of the Company’s business affairs
and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision to acquire the Shares. MD Anderson is purchasing the Shares for investment for MD Anderson’s own account only and
not with a view to, or for resale in connection with, any “distribution” thereof within the meaning of the Act. 

(ii)    MD Anderson understands that the Shares have not been registered under the Act by reason of a specific
exemption therefrom, which exemption depends upon, among other things, the bona fide nature of MD Anderson’s investment intent as expressed herein. 

(iii)    MD Anderson further acknowledges and understands that the Shares must be held indefinitely unless the
Shares are subsequently registered under the Act or an exemption from such registration is available. MD Anderson further acknowledges and understands that the Company is under no obligation to register the Shares. MD Anderson understands that the
certificate(s) evidencing the Shares will be imprinted with a legend that prohibits the transfer of the Shares unless the Shares are registered or such registration is not required in the opinion of counsel for the Company. 

(iv)    MD Anderson is familiar with the provisions of Rule 144 under the Act, as in effect from time to time,
which, in substance, permits limited public resale of “restricted securities” acquired, directly or indirectly, from the issuer thereof (or from an affiliate of such issuer), in a non-public offering
subject to the satisfaction of certain conditions. The Shares may be resold by MD Anderson in certain limited circumstances subject to the provisions of Rule 144, which requires, among other things: (A) the availability of certain public
information about the Company; and (B) the resale occurring following the required holding period under Rule 144 after MD Anderson has purchased, and made full payment for (within the meaning of Rule 144), the securities to be sold. 

(v)    MD Anderson further understands that at the time MD Anderson wishes to sell the Shares there may be no
public market upon which to make such a sale, and that, even if such a public market then exists, the Company may not be satisfying the current public information requirements of Rule 144, and that, in such event, MD Anderson would be precluded from
selling the Shares under Rule 144 even if the minimum holding period requirement had been satisfied. 

(b)    The Company represents and warrants to MD Anderson that the statements contained in this Section 8(b)
are true and correct as of the date hereof. 
 (i)    The Company is a corporation duly formed, validly existing
and in good standing under the Laws of the State of Delaware. The Company is duly authorized and qualified to do business under all applicable Laws, regulations, ordinances and orders of public authorities to carry on its business in the places and
in the manner as now conducted, except where the failure to be so authorized or qualified could not reasonably be expected to materially impair, delay or prevent the consummation of the transactions contemplated by this Agreement. 

  
 13 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

(ii)    The Company has all requisite corporate power and authority to enter into this Agreement and to perform its
obligations hereunder and to consummate the transactions contemplated hereby. The execution and delivery by the Company of this Agreement and its consummation of the transactions contemplated hereby have been duly authorized by all necessary
corporate action of the Company. This Agreement has been duly executed and delivered by the Company and constitutes, and when executed and delivered by MD Anderson, will constitute, the legal, valid and binding obligation of the Company, enforceable
against the Company in accordance with its terms, except as may be limited by applicable bankruptcy, insolvency, reorganization, moratorium and other similar Laws of general application to creditors. 

(iii)    The execution, delivery and performance of this Agreement, and the consummation of the transactions
contemplated hereby, do not and will not: (A) result in a breach or violation of any provision of the certificate of incorporation or bylaws or other organizational documents of the Company; (B) conflict with or result in a violation or
breach of any provision of any Law or Governmental Order applicable to the Company; or (C) require the consent, notice or other action by any Person under, conflict with, result in a violation or breach of, constitute a default or an event
that, with or without notice or lapse of time or both, would constitute a default under, result in the acceleration of or create in any party the right to accelerate, terminate, modify or cancel any contract, Permit or other agreement to which the
Company is a party or by which the Company is bound or to which its properties and assets are subject; except in the cases of clauses (B) and (C), where the violation, breach, conflict, default, acceleration or failure to give notice would not,
individually or in the aggregate, reasonably be expected to materially impair, delay or prevent the consummation of the transactions contemplated by this Agreement. 

(iv)    No consent, approval, order or authorization of, or registration, declaration or filing with, or notice to,
any Person is required to be obtained by the Company or any affiliate of the Company in connection with the execution and delivery of this Agreement and the consummation by the Company of the transactions contemplated hereby, except for such
consents, approvals, orders, authorizations, registrations, declarations or filings the failure of which to be obtained or made could not, individually or in the aggregate, reasonably be expected to materially impair, delay or prevent the
consummation of the transactions contemplated by this Agreement. 
 (v)    The authorized capital stock of the
Company consists of [***] shares of Common Stock, of which [***] shares are issued and outstanding immediately prior to the Initial Closing. The issuance and delivery of the Shares by the Company pursuant to this Agreement have been duly authorized
by all necessary action by the Company. The Shares, when issued and delivered in accordance with the terms and for the consideration set forth in this Agreement, will be validly issued, fully paid and nonassessable and free of any liens, claims or
other encumbrances, except for restrictions on transfer provided for herein or under the Act or other applicable securities Laws. Assuming the accuracy of the representations of MD Anderson in Section 8(a) of this Agreement, the Shares will be
issued in compliance with all applicable federal and state securities Laws. None of the Shares, when issued, will violate any agreement, arrangement or commitment to which the Company is a party or is subject to or violate any preemptive or similar
rights of any Person. There are no outstanding or authorized options, warrants, convertible securities or other rights, agreements, arrangements or commitments of any character relating to the capital stock of the Company or obligating the Company
to issue or sell any shares of capital stock of, or any other interest in, the Company. The Company does not have outstanding or authorized any stock appreciation, phantom stock, profit participation or similar rights. There are no voting trusts,
stockholder agreements, proxies or other agreements or understandings in effect with respect to the voting or transfer of any of the Shares. 

(vi)    There is no Action pending, or to the Company’s knowledge, threatened: (A) against the Company
affecting any of its properties or assets; or (B) against the Company that challenges or seeks to prevent, enjoin or otherwise delay the transactions contemplated by this Agreement. To the knowledge of the Company, no event has occurred or
circumstances exist that may give rise to, or serve as a basis for, any such Action. 

  
 14 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

(vii)    The Company has complied, and is now complying, in each case in all material respects, with all Laws
applicable to it or its business, properties or assets. 
 (viii)    All Permits required for the Company to
conduct its business as currently conducted have been obtained by it and are valid and in full force and effect. All fees and charges with respect to such Permits as of the date hereof have been paid in full. To the knowledge of the Company, no
event has occurred that, with or without notice or lapse of time or both, would reasonably be expected to result in the revocation, suspension, lapse or limitation of any Permit. 

(ix)    As of the date hereof, the Company has no material liability or obligation, absolute or contingent
(individually or in the aggregate), except liabilities directly arising under the Transaction Documents.

9.        PUT-CALL
OPTION. Each party hereto agrees to be bound by and consents to the put-call option granted with respect to the Shares on the terms and conditions set forth in
Exhibit C to this Agreement, it being understood that the Authorized Capital (as defined in Exhibit C) and the approval of the granting of subscription rights to shares of Parent Common Stock (as
defined in Exhibit C) to MD Anderson shall be resolved by the Shareholders’ Meeting of Parent within 60 days after the date hereof. 

10.      MARKET STAND-OFF
AGREEMENT. Neither MD Anderson nor Parent shall sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale,
any Common Stock or other securities of the Company held by (or for the benefit of) MD Anderson or Parent (other than those included in the registration), including the Shares (the “Restricted Securities”), during the 180-day period following the effective date of the Company’s first firm commitment underwritten public offering of its Common Stock (or such longer period, not to exceed thirty-four (34) days after the
expiration of the 180-day period, as the underwriters or the Company shall request in order to facilitate compliance with NASD Rule 2711 or NYSE Member Rule 472 or any successor or similar rule or regulation)
(the “Lock Up Period”); provided, however that nothing contained in this Section 10 shall prevent the exercise of the Purchase Right during the Lock Up Period. Each of MD Anderson and Parent agrees to execute and deliver
such other agreements as may be reasonably requested by the Company and/or the managing underwriters which are consistent with the foregoing or which are necessary to give further effect thereto. In order to enforce the foregoing covenant, the
Company may impose stop-transfer instructions with respect to MD Anderson’s and Parent’s Restricted Securities until the end of such period. The underwriters of the Company’s stock are intended third party beneficiaries of this
Section 10 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. 

11.      SECTION 83(B) ELECTION. MD Anderson understands that
Section 83(a) of the Internal Revenue Code of 1986, as amended (the “Code”), taxes as ordinary income the difference between the amount paid for the Initial Shares and the fair market value of the Initial Shares as of
the date any restrictions on the Initial Shares lapse. In this context, “restriction” includes the right of the Company to purchase the Initial Shares pursuant to the Purchase Right set forth in Section 1(b) above. MD Anderson
understands that MD Anderson may elect to be taxed at the time the Initial Shares are issued, rather than when and as the Purchase Right expires, by filing an election under Section 83(b) (an “83(b) Election”) of the
Code with the Internal Revenue Service within thirty (30) days from the date of issuance. Even if the fair market value of the Initial Shares at the time of the execution of this Agreement equals the amount paid for the Initial Shares, the
83(b) Election must be made to avoid income under Section 83(a) in the future. MD Anderson understands that failure to file such an 83(b) Election in a timely manner may result in adverse tax consequences for MD Anderson. MD Anderson further
understands that an additional copy of such 83(b) Election is required to be filed with its 

  
 15 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

federal income tax return for the calendar year in which the date of this Agreement falls. MD Anderson further acknowledges and understands
that it is MD Anderson’s sole obligation and responsibility to timely file such 83(b) Election, and neither the Company nor the Company’s
legal or financial advisors shall have any obligation or responsibility with respect to such filing. MD Anderson acknowledges that the foregoing is only a summary of the effect of United States federal income taxation with respect to
issuance of the Initial Shares hereunder, and does not purport to be complete. MD Anderson further acknowledges that the Company has directed MD Anderson to seek independent advice regarding the applicable provisions of the Code and the income tax
laws of any municipality, state or foreign country in which MD Anderson may reside. MD Anderson assumes all responsibility for filing an 83(b) Election and paying all taxes resulting from such election or the lapse of the restrictions on the Initial
Shares. 
 12.    REFUSAL TO TRANSFER. The Company shall not be required:
(a) to transfer on its books any Shares of the Company which shall have been transferred in violation of any of the provisions set forth in this Agreement; or (b) to treat as owner of such shares or to accord the right to vote as such
owner or to pay dividends to any transferee to whom such shares shall have been so transferred. 
 13.    NO
COLLABORATION RIGHTS. This Agreement shall not affect in any manner whatsoever the right or power of the Company (or a parent or subsidiary of the Company) or of MD Anderson to terminate the Collaboration Agreement
pursuant to the terms thereof, either prior to or following the attainment of any applicable Milestones. 

14.    CONFLICTS. Notwithstanding anything contained herein to the contrary, if MD Anderson is or becomes a
party to any stockholders’, right of first refusal, voting or similar agreement with the Company and other stockholders of the Company (any such agreement, a “Shareholders’ Agreement”),
the terms of any such Shareholders’ Agreement shall supersede the terms of this Agreement in the event of (but only to the extent of) any conflict between the provisions hereof and thereof. 

15.    TERMINATION. The rights and obligations of MD Anderson and the Parent set forth in Sections 4, 5 and 6
shall terminate upon the consummation of an initial public offering by the Company. 
  

	16.	 MISCELLANEOUS. 

(a)    Notices. All notices required or permitted hereunder shall be in writing and shall be deemed
effectively given: (i) upon personal delivery to the party to be notified; (ii) when sent by confirmed telex, facsimile or electronic mail if sent during normal business hours of the recipient, and if not during normal business hours of
the recipient, then on the next business day; (iii) five (5) calendar days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after deposit with a
nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the other party hereto at such party’s address hereinafter set forth on the signature page hereof,
or at such other address as such party may designate by ten (10) days advance written notice to the other party hereto. 

(b)    Successors and Assigns. This Agreement shall inure to the benefit of the successors and assigns of
the Company and, subject to the restrictions on transfer herein set forth, be binding upon MD Anderson, and MD Anderson’s successors and assigns. The Purchase Right of the Company hereunder shall be assignable by the Company at any time or from
time to time, in whole or in part. 
 (c)    Specific Performance. It is the intention of the parties that
the Company, upon exercise of the Purchase Right and payment therefor, pursuant to the terms of this Agreement, shall be 

  
 16 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

entitled to receive the Purchase Shares, in specie, in order to have such Purchase Shares available for future issuance without dilution of the holdings of
other stockholders. Furthermore, it is expressly agreed between the parties that money damages are inadequate to compensate the Company for the Purchase Shares and that the Company shall, upon proper exercise of the Purchase Right, be entitled to
specific enforcement of its rights to purchase and receive said Purchase Shares. 
 (d)    Governing
Law; Venue. This Agreement shall be governed by and construed in accordance with the Laws of the State of Delaware. The parties agree that any action brought by either party to interpret or enforce any provision of this Agreement
shall be brought in, and each party agrees to, and does hereby, submit to the jurisdiction and venue of, the appropriate state or federal court for the district encompassing the Company’s principal place of business. 

(e)    Further Execution. The parties agree to take all such further action(s) as may reasonably be
necessary to carry out and consummate this Agreement as soon as practicable, and to take whatever steps may be necessary to obtain any required approval from a Governmental Authority in connection with or otherwise qualify the issuance of the
securities that are the subject of this Agreement. 
 (f)    Independent Counsel. MD Anderson acknowledges
that this Agreement has been prepared on behalf of the Company by Cooley LLP, counsel to the Company and that Cooley LLP does not represent, and is not acting on behalf of, MD Anderson. MD Anderson has been provided with an opportunity to consult
with MD Anderson’s own counsel with respect to this Agreement. 
 (g)    Entire Agreement; Amendment.
This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes and merges all prior agreements or understandings, whether written or oral. Notwithstanding the foregoing this Agreement
does not supersede or merge any terms of the Collaboration Agreement nor shall it interfere with the parties’ rights to terminate the Collaboration Agreement in accordance with its terms. This Agreement may not be amended, modified or revoked,
in whole or in part, except by an agreement in writing signed by each of the parties hereto. 

(h)    Severability. If one or more provisions of this Agreement are held to be unenforceable under
applicable Law, the parties agree to renegotiate such provision in good faith. In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then: (i) such provision shall be excluded from this
Agreement; (ii) the balance of the Agreement shall be interpreted as if such provision were so excluded; and (iii) the balance of the Agreement shall be enforceable in accordance with its terms. 

(i)    Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be
deemed an original and all of which together shall constitute one instrument. 
 (j)    Texas State Agency.
MD Anderson is an agency of the State of Texas and under the constitution and Laws of the State of Texas possesses certain rights and privileges, is subject to certain limitations and restrictions, and only has such authority as is granted to it
under the constitution and Laws of the State of Texas. Notwithstanding any provision hereof, nothing in this Agreement is intended to be, nor will it be construed to be, a waiver of the sovereign immunity of the State of Texas or a prospective
waiver or restriction of any of the rights, remedies, claims, and privileges of the State of Texas. Moreover, notwithstanding the generality or specificity of any provision hereof, the provisions of this Agreement as they pertain to MD Anderson are
enforceable only to the extent authorized by the constitution and Laws of the State of Texas; accordingly, to the extent any provision hereof conflicts with the constitution or Laws of the State of Texas or exceeds the right, power or authority of
MD Anderson to agree to such provision, then that provision will not be enforceable against MD Anderson or the State of Texas. 

  
 17 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

(k)      Certain Definitions. When used in this Agreement with initial capital letters, the
following terms used herein have the meanings specified or referred to in this Section 16(k). 

(i)    “83(b) Election” has the meaning set forth in Section 11.

 (ii)    “Acquisition” has the meaning set forth in Section 1(e). 

(iii)    “Act” has the meaning set forth in Section 4(a). 

(iv)    “Action” means any claim, action, cause of action, demand, lawsuit, arbitration,
inquiry, audit, notice of violation, proceeding, litigation, citation, summons, subpoena or investigation of any nature, civil, criminal, administrative, regulatory or otherwise, whether at law or in equity. 

(v)     “Agreement” has the meaning set forth in the introductory paragraph to this
Agreement. 
 (vi)    “Asset Transfer” has the meaning set forth in Section 1(e).

 (vii)    “Closing” has the meaning set forth in Section 2(a). 

(viii)    “Code” has the meaning set forth in Section 11. 

(ix)    “Collaboration Agreement” has the meaning set forth in Section 1(a). 

(x)    “Common Stock” has the meaning set forth in Section 1(a). 

(xi)    “Company” has the meaning set forth in the introductory paragraph to this
Agreement. 
 (xii)    “Company Notice” has the meaning set forth in Section 4(b).

 (xiii)    “Completed Subsequent Milestones” has the meaning set forth in
Section 2(a). 
 (xiv)    “Corporate Transaction” has the meaning set forth in
Section 1(e). 
 (xv)    “Cumulative FF&E Payments” has the meaning set forth in
Section 1(f)(ii). 
 (xvi)    “Current Ratio” means the ratio of (A) the sum of
all shares of Common Stock held by a holder of Common Stock (including for this purpose any shares of Common Stock or other equity securities which could be acquired upon conversion of any securities convertible into Common Stock or other equity
securities or exercise of any rights to acquire Common Stock or other equity securities), to (B) all outstanding shares of Common Stock (including for this purpose any shares of Common Stock or other equity securities which could be acquired
upon conversion of any of the Company’s securities convertible into Common Stock or other equity securities or exercise of any rights issued by the Company to acquire Common Stock or other equity securities). 

(xvii)     “Escrow Agent” has the meaning set forth in Section 1(h). 

(xviii)    “Excluded Issuance” means (A) any shares of Common Stock, options or
convertible securities issued as stock dividends or pursuant to stock splits, recapitalization or other similar events that do not adversely affect the Current Ratio of the holders of Common Stock; (B) securities issued pursuant to a public
offering; (C) Common Stock issuable directly to, or upon the 

  
 18 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

exercise of any warrants or options held by, employees, consultants or other service providers of the Company as compensation or otherwise; (D) securities
issued by the Company as consideration in a merger, stock purchase, asset acquisition or similar transaction with an unaffiliated party; (E) shares of Common Stock or convertible securities actually issued upon the exercise of options or shares
of Common Stock actually issued upon the conversion or exchange of convertible securities, in each case provided such issuance is pursuant to the terms of such option or convertible security; (F) shares of Common Stock, options or convertible
securities issued to banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction (including shares underlying (directly or indirectly)
any such options or convertible securities); and (G) shares of Common Stock, options or convertible securities issued (i) to suppliers or third party service providers in connection with the provision of goods or services and (ii) in
connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships. 

(xix)    “GAAP” means United States generally accepted accounting principles in effect from
time to time. 
 (xx)    “Governmental Authority” means any federal, state, local or
foreign government or political subdivision thereof, or any agency or instrumentality of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory
authority or quasi-governmental authority (to the extent that the rules, regulations or orders of such organization or authority have the force of Law), or any arbitrator, court or tribunal of competent jurisdiction. 

(xxi)    “Governmental Order” means any order, writ, judgment, injunction, decree,
stipulation, determination or award entered by or with any Governmental Authority. 

(xxii)    “FF&E Payment” has the meaning set forth in Section 1(f)(i). 

(xxiii)    “Initial Closing” has the meaning set forth in Section 1(a). 

(xxiv)    “Initial Determination Date” has the meaning set forth in Section 1(b). 

(xxv)    “Initial Milestone” and “Initial Milestones” have the
meanings set forth in Section 1(b). 
 (xxvi)    “Initial Milestone Difference” has
the meaning set forth in Section 1(f)(iv). 
 (xxvii)    “Initial Milestone Dollar
Value” has the meaning set forth in Section 1(b). 
 (xxviii)    “Initial Milestone
Negative Difference” has the meaning set forth in Section 1(f)(iv)(B). 

(xxix)    “Initial Milestone Positive Difference” has the meaning set forth in
Section 1(f)(iv)(A). 
 (xxx)    “Initial Per Share Stock Price” has the meaning set
forth in Section 1(a). 
 (xxxi)    “Initial Shares” has the meaning set forth in
Section 1(a). 
 (xxxii)    “Law” means any statute, law, ordinance, regulation,
rule, code, order, constitution, treaty, common law, judgment, decree, other requirement or rule of law of any Governmental Authority. 

  
 19 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

(xxxiii)    “Sublease Agreement” has the meaning set forth in Section 1(f)(i). 

(xxxiv)    “License Agreement” has the meaning set forth in Section 2(b). 

(xxxv)    “License Agreement Shares” has the meaning set forth in Section 2(b). 

(xxxvi)    “Lock Up Period” has the meaning set forth in Section 10. 

(xxxvii)    “Majority Stockholders” has the meaning set forth in Section 5(a)(i). 

(xxxviii)    “Milestones” has the meaning set forth in Section 1(b). 

(xxxix)    “Milestone Shares” has the meaning set forth in Section 2(a). 

(xl)    “Net Cumulative FF&E Payments” has the meaning set forth in
Section 1(f)(iii). 
 (xli)    “New Securities” has the meaning set forth in
Section 6(a). 
 (xlii)    “Partially Performed Initial Milestone” has the meaning
set forth in Section 1(b). 
 (xliii)    “Partially Performed Subsequent Milestone”
has the meaning set forth in Section 2(a). 
 (xliv)    “Permits” means all permits,
licenses, franchises, approvals, authorizations, registrations, certificates, variances and similar rights obtained, or required to be obtained, from Governmental Authorities. 

(xlv)    “Person” means an individual, corporation, partnership, joint venture, limited
liability company, Governmental Authority, unincorporated organization, trust, association or other entity. 

(xlvi)    “Pro Rata Portion” has the meaning set forth in Section 5(b)(iv). 

(xlvii)    “Proposed Transfer” has the meaning set forth in Section 4(a). 

(xlviii)    “Proposed Transferee” has the meaning set forth in Section 5(b)(i). 

(xlix)    “Proposed Transfer Notice” has the meaning set forth in Section 4(b). 

(l)    “Prospective Transferee” has the meaning set forth in Section 4(a). 

(li)    “Purchase Price” has the meaning set forth in Section 1(b). 

(lii)    “Purchase Right” has the meaning set forth in Section 1(b). 

(liii)    “Purchase Shares” has the meaning set forth in Section 1(b). 

(liv)    “Restricted Securities” has the meaning set forth in Section 10. 

(lv)    “Right of First Offer” has the meaning set forth in Section 4(a). 

(lvi)    “Selling Holders” has the meaning set forth in Section 5(a)(iii). 

  
 20 

 THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED 

INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) 

NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE 

COMPANY IF PUBLICLY DISCLOSED 
  

(lvii)    “Shares” has the meaning set forth in Section 2(b). 

(lviii)    “Shareholders’ Agreement” has the meaning set
forth in Section 14. 
 (lix)    “Subsequent Closing” has the meaning set forth in
Section 2(a). 
 (lx)    “Subsequent Determination Date” has the meaning set forth
in Section 2(a). 
 (lxi)    “Subsequent Milestone Difference” has the meaning set
forth in Section 2(c)(ii). 
 (lxii)    “Subsequent Milestone Negative Difference”
has the meaning set forth in Section 2(c)(ii)(B). 
 (lxiii)    “Subsequent Milestone Positive
Difference” has the meaning set forth in Section 2(c)(ii)(A). 

(lxiv)    “Subsequent Milestones” has the meaning set forth in
Section 2(a). 
 (lxv)    “Subsequent Milestone Per Share Price” has the meaning set
forth in Section 2(a). 
 (lxvi)    “Tag-Along Exercise
Notice” has the meaning set forth in Section 5(b)(iii). 
 (lxvii)    “Tag-Along Period” has the meaning set forth in Section 5(b)(iii). 

(lxviii)    “Tag-Along Sale” has the meaning set
forth in Section 5(b)(i). 
 (lxix)    “Tag-Along Sale
Notice” has the meaning set forth in Section 5(b)(ii). 
 (lxx)    “Tag-Along Stockholder” has the meaning set forth in Section 5(b)(i). 

(lxxi)    “Transaction Documents” means each of the following: (a) this Agreement;
(b) the Stock Purchase Agreement between the Company and Parent; (c) the Employment Offer Letter & Proprietary Information and Inventions Assignment Agreements with current and proposed employees of the Company; (d) the
Exclusive License and Service Agreement with Parent; (e) the Collaboration Agreement; (f) the Indemnification Agreement with each of the directors of the Company; (g) (IL21 - MDA[***]) Sublicense Agreement with MD Anderson;
(h) (Gamma Delta T cells - MDA[***]) License Agreement with MD Anderson; (i) (Fratricide – MDA[***]) Option Agreement with MD Anderson; (j) (Mispairing - MDA[***], MDA[***], and MDA[***]) Option Agreement with MD Anderson;
(k) (2D3 Chimeric ab-gd - MDA[***], MDA[***], and MDA[***]) Option Agreement with MD Anderson; (l) (FHCRC – MDA[***]) Option Agreement with MD Anderson; and (m) K562 Option Agreement. 

(lxxii)    “Transfer Stock” has the meaning set forth in Section 4(a). 

(lxxiii)    “Uncompleted Initial Milestone” has the meaning set forth in
Section 1(b). 
 [SIGNATURE PAGE FOLLOWS] 

  
 21 

 IN WITNESS WHEREOF, the parties hereto
have executed this Agreement as of the day and year first above written. 
  

			
	IMMATICS US, INC.

 
			
		
	By:	 	 /s/ Harpreet Singh

			
	Name:	 	 Dr. Harpreet Singh

			
	Title:	 	 Chief Executive Officer

			
		
	Address:	 	700 Milam St., Suite 1300
		 	Houston TX 77002

  

							
	IMMATICS BIOTECHNOLOGIES GMBH
	(for purposes of Sections 1(d), 2, 5, 9 and 10)
				
	By:	 	 /s/ Rainer Kramer
	 	    	 	 /s/ Carsten Reinhardt

	Name:	 	 Dr. Rainer Kramer
	 		 	 Dr. Carsten Reinhardt

	Title:	 	 Managing Director/CBO
	 		 	 Managing Director/CMO

				
	Address:	 	  
	 		 	  

		 	  
	 		 	  

 SUBJECT TO SECTION 1(E) OF
THIS AGREEMENT, MD ANDERSON ACKNOWLEDGES AND AGREES THAT THE VESTING OF THE
INITIAL SHARES PURSUANT TO SECTION 1(B) HEREOF IS EARNED ONLY BY
ATTAINMENT OF THE INITIAL MILESTONES. MD ANDERSON FURTHER ACKNOWLEDGES AND AGREES
THAT NOTHING IN THIS AGREEMENT SHALL CONFER UPON MD ANDERSON ANY RIGHT
WITH RESPECT TO CONTINUATION OF THE COLLABORATION AGREEMENT, NOR SHALL IT
INTERFERE IN ANY WAY WITH MD ANDERSON’S RIGHT OR THE
COMPANY’S RIGHT TO TERMINATE THE COLLABORATION AGREEMENT PURSUANT TO THE
TERMS THEREOF. 
 SUBJECT TO THE TERMS OF
THIS AGREEMENT, MD ANDERSON ACKNOWLEDGES AND AGREES THAT MD ANDERSON MUST HOLD THE
COMMON STOCK ISSUED HEREUNDER INDEFINITELY, AND THAT THE COMPANY HAS NO
OBLIGATION TO PURCHASE SUCH SHARES. MD ANDERSON FURTHER ACKNOWLEDGES THAT ANY RISK
RELATED TO THE FLUCTUATION IN THE VALUE OF THE SHARES FROM AND
AFTER THE DATE HEREOF, INCLUDING ANY LOSSES TO MD ANDERSON AS A
RESULT OF COMPANY’S EXERCISE OF ITS PURCHASE RIGHT PURSUANT TO
SECTION 1(B), SHALL BE BORNE BY MD ANDERSON. 

MD ANDERSON ACKNOWLEDGES THAT MD ANDERSON HAS READ
ALL TAX RELATED SECTIONS AND FURTHER ACKNOWLEDGES MD ANDERSON HAS HAD AN
OPPORTUNITY TO CONSULT MD ANDERSON’S OWN TAX, LEGAL AND FINANCIAL ADVISORS
REGARDING THE ISSUANCE OF COMMON STOCK UNDER THIS AGREEMENT. 

MD ANDERSON ACKNOWLEDGES AND AGREES THAT IN MAKING
THE DECISION TO ACQUIRE THE SHARES HEREUNDER MD ANDERSON HAS NOT RELIED
ON ANY STATEMENT, WHETHER WRITTEN OR ORAL, REGARDING THE SUBJECT MATTER
HEREOF, EXCEPT AS EXPRESSLY PROVIDED HEREIN AND IN THE ATTACHMENTS AND
EXHIBITS HERETO. 

 
			
	THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM,
FOR THE BENEFIT OF THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER
CENTER

 
			
		
	By:	 	 /s/ Ronald A. DePinho

			
	Name:	 	 Ronald A. DePinho, MD

			
	Title:	 	President

 
			
		
	Address:	 	1515 Halcombe Blvd., Houston, TX 77030

 EXHIBIT A-1 

INITIAL MILESTONES 

[***] 
 *** Company and MD Anderson
acknowledge and agree that the Initial Milestone of [***] will be completed upon signing and delivery of the Collaboration Agreement, and will not be subject to (i) any Purchase Rights (as defined in Section 1(b)), or
(ii) any right to be credited against FF&E Payments as set forth in Section 1(f).  

 EXHIBIT A-2
SUBSEQUENT MILESTONES 
 [***] 

 EXHIBIT B 

STOCK ASSIGNMENT SEPARATE FROM CERTIFICATE 

FOR VALUE RECEIVED, THE BOARD OF
REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, FOR THE BENEFIT OF THE
UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER hereby sells, assigns and transfers unto IMMATICS US,
INC., a Delaware corporation (the “Company”), pursuant to the Purchase Right under that certain Restricted Stock Acquisition Agreement, dated as of August [●], 2015 (as amended, restated, modified
and/or extended, the “Agreement”), by and between the undersigned and the Company [●] shares of Common Stock of the Company standing in the undersigned’s name on the books of the Company represented by Certificate
No(s).                     . This Assignment may be used only in accordance with and subject to the terms and conditions of the Agreement, in
connection with the purchase of shares of Common Stock issued to the undersigned pursuant to the Agreement, and only to the extent that such shares remain subject to the Company’s Purchase Right under the Agreement. 

Dated:                      

 

			
	THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, FOR THE BENEFIT OF THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER

			
		
	By:	 	  

 
			
	Name:	 	  

 
			
	Title:	 	  

 EXHIBIT C 

TERMS AND CONDITIONS OF PUT-CALL OPTION 

The Board of Regents of the University of Texas System, for the benefit of the University of Texas M. D. Anderson Cancer Center (“MD
Anderson”) desires to have the right to exchange all of the Shares held by (or for the benefit of) MD Anderson at the time of a Parent Exit Event (including without limitation, the unvested Initial Shares) and immatics
biotechnologies GmbH (“Parent”) desires to have the right to acquire all of the Shares held by (or for the benefit of) MD Anderson at the time of a Parent Exit Event (including without limitation, the unvested Initial
Shares), each on the terms and conditions set forth in this Exhibit C. 
 Section 1.1    Definitions.
When used in this Exhibit C with initial capital letters, the following terms used herein have the meanings set forth in this Section 1.1. 
  

	(a)	 “Appraiser” means a business valuation expert who is: (i) independent of all
parties to the Agreement; (ii) employed by a nationally recognized valuation or investment banking firm regularly involved in providing valuations of businesses of a similar nature as Parent and/or the Company; and (iii) holds a recognized
appraisal credential such as the Accredited Senior Appraiser (ASA) designation of the American Society of Appraisers. For the avoidance of doubt, [***]and its affiliates shall not be considered eligible to be the Appraiser under this Agreement.

  

	(b)	 “Authorized Capital” means the authorization of the Managing Directors of Parent to
increase the share capital of Parent with the approval of the Board of Directors (Beirat) of Parent (the “Board”) up until May 31, 2020, once or several times by in total up to [***] in return for contributions in
cash and/or in kind by the issue of in total up to [***] new shares of Parent Common Stock under exclusion of the statutory subscription rights of the shareholders of Parent, whereby only MD Anderson shall be invited to subscribe for the new shares
of Parent Common Stock out of the Authorized Capital. 

  

	(c)	 “Authorized Capital Increase” has the meaning set forth in Section 1.5(a) to this
Exhibit C. 

  

	(d)	 “Board” has the meaning set forth in Section 1.1(a) to this Exhibit C.

  

	(e)	 “Call Election Notice” has the meaning set forth in Section 1.2 to this Exhibit C.

  

	(f)	 “Call Option” has the meaning set forth in Section 1.2 to this Exhibit C.

  

	(g)	 “ELSA” means that certain Exclusive License & Services Agreement dated as of
August [__], 2015, by and between the Parent and the Company. 

  

	(h)	 “Exchange Options” means the Put Option and the Call Option. 

 

	(i)	 “Exchange Ratio” means the quotient of the then applicable FMV of one Exchangeable
Share divided by the then applicable FMV of one share of Parent Common Stock. By way of example and not limitation, the Exchange Ratio would be [***] if the then applicable FMV of one Exchangeable Share was [***] per share and the then applicable
FMV of one share of Parent Common Stock was [***] per share. By way of further example and not limitation, the Exchange Ratio would be [***] if the then applicable FMV of one Exchangeable Share was [***] per share and the then applicable

	 	
FMV of one share of Parent Common Stock was [***] per share. For purposes of determining the applicable Exchange Ratio, the applicable FMV of one Exchangeable Share shall first be converted to
Euro using the United States Dollars - Euro exchange rate as published in The Wall Street Journal, Eastern Edition, on the date that is two (2) Business Days prior to the date on which the Managing Directors of Parent resolve the Authorized
Capital Increase. As used herein, “Business Day” means any day except Saturday or Sunday or a day on which the banks in New York City, New York or Stuttgart, Germany are required or entitled by applicable law to be closed.

  

	(j)	 “Exchangeable Shares” means the Shares subject to the Put Option or the Call Option, as
applicable. 

  

	(k)	 “Execution Notice” has the meaning set forth in Section 1.5(b) to this Exhibit C.

  

	(l)	 “ELSA Event” has the meaning set forth in Section 1.4(a) to this Exhibit C.

  

	(m)	 “ELSA Event Notice” has the meaning set forth in Section 1.4(a) to this Exhibit C.

  

	(n)	 “Fair Market Value” means the price, expressed in terms of cash equivalents, at which
property would change hands between a hypothetical willing and able buyer and a hypothetical willing and able seller, acting at arm’s length in an open and unrestricted market, when neither is under compulsion to buy or sell and when both have
reasonable knowledge of the relevant facts. Fair Market Value shall be determined on a going concern basis and on a pro rata basis (i.e., without the application of any discount for lack of control or lack of marketability). Further, the Appraiser
shall use generally accepted business valuation methods and principles, applied on a consistent basis, and shall take into account the relative rights, and preferences affecting the Exchangeable Shares or shares of Parent Common Stock, as the case
may be. Notwithstanding the foregoing or anything else to the contrary herein: (i) in determining the FMV of Parent Common Stock, the Appraiser shall disregard any and all liquidation, sale and dividend preference amounts payable to any
equityholder of Parent with respect to equity capital of Parent held by them from time to time (so that any such liquidation, sale and dividend preference amounts are not taken into account and do not affect the FMV of the Parent Common Stock); and
(ii) in determining the FMV of Exchangeable Shares or the Parent Common Stock, the Appraiser shall disregard any proposed or otherwise potential Termination License Event (so that the potential termination of the ELSA is not taken into account
and does not affect the FMV of the Exchangeable Shares or the Parent Common Stock). 

  

	(o)	 “FMV” means the Fair Market Value per share, in the case of Exchangeable Shares in U.S.
Dollars and in the case of Parent Common Stock in Euros, as most recently determined by the Appraiser within the six (6) calendar months prior to delivery of a Put Election Notice, Call Election Notice or Parent Exit Event Notice or pursuant to
Section 1.9 of this Exhibit C. 

  

	(p)	 “Parent Common Stock” means shares of the common stock of Parent
(Stammgeschäftsanteile), with [***] par value per share. 

  

	(q)	 “Parent Exit Event” means any of the following: (i) a merger or consolidation in
which (a) the Parent is a constituent party or (b) a subsidiary of the Parent (other than the Company) is a constituent party and the Parent issues shares of its capital stock pursuant to such merger or consolidation, except any such
merger or consolidation involving the Parent or a subsidiary in which the shares of capital stock of the Parent outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of
capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (1) the surviving or resulting corporation or (2) if the surviving or resulting corporation is
a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of 

	 	
such surviving or resulting corporation; (ii) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Parent or
any subsidiary of the Parent (other than the Company) of all or substantially all the assets of the Parent and its subsidiaries taken as a whole or the sale or disposition (whether by merger or otherwise) of one or more subsidiaries of the Parent
(other than the Company) if substantially all of the assets of the Parent and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a
wholly owned subsidiary of the Parent; (iii) any transaction or series of related transactions in which in excess of fifty percent (50%) of the Parent’s then outstanding voting power is transferred; or (iv) the closing of a public
offering of Parent Common Stock (or the equity of any newly formed parent entity of the Parent formed for the purpose of consummating a public offering of Parent or the equity of any entity into which Parent is converted (formwechselnde
Umwandlung) in accordance with the provisions of the German Act on Transformations of Companies (UmwG)) on an internationally recognized stock exchange (a “Parent IPO”). 

 

	(r)	 “Parent Exit Event Notice” has the meaning set forth in Section 1.4(b) to this
Exhibit C. 

  

	(s)	 “Put Election Notice” has the meaning set forth in Section 1.2 to this Exhibit C.

  

	(t)	 “Put Option” has the meaning set forth in Section 1.2 to this Exhibit C.

  

	(u)	 “Required Information” has the meaning set forth in Section 1.4(b) to this Exhibit
C. 

  

	(v)	 “Subscription Declaration” has the meaning set forth in Section 1.5(b)(i) to this
Exhibit C. 

  

	(w)	 “Subscription Shares” has the meaning set forth in Section 1.3 to this Exhibit C.

  

	(x)	 “Termination License Event” means any of the following: (i) the termination of the
ELSA, (ii) a material and adverse reduction of rights in the license provided to the Company pursuant to Section 7.1 of the ELSA, and/or (iii) modifications or amendments to the ELSA that are functionally equivalent to the events
described in (i) or (ii) of this definition. 

  

	(y)	 “Transfer Documents” has the meaning set forth in Section 1.5(b) to this Exhibit
C. 

 Section 1.2    Put Option – Call Option. Subject to the terms and
conditions set forth in this Exhibit C, including without limitation the time periods set forth in Section 1.4 to this Exhibit C, Parent hereby grants to MD Anderson an irrevocable right and option (the “Put
Option”), and MD Anderson hereby grants to Parent an irrevocable right and option to require MD Anderson (the “Call Option”), to subscribe for shares of Parent Common Stock out of the
Authorized Capital Increase against the exchange, conveyance, transfer and assignment of all (but not less than all) of the vested and unvested Shares held by (or for the benefit of) MD Anderson (after giving effect to any and all adjustments in
accordance with Section 1(f) and/or Section 2(c) determined as of the date of delivery of the Put Election Notice or Call Election Notice, as applicable) at the time of the first Parent Exit Event following the date hereof with the intent
that all unvested Initial Shares held by or for the benefit of MD Anderson shall be accelerated for purposes of the Put Option and the Call Option. In addition, and subject to the terms and conditions set forth in this Exhibit C, including
without limitation the time periods set forth in Section 1.4 to this Exhibit C, MD Anderson, in its sole discretion, shall have a Put Option to subscribe for shares of Parent Common Stock out of the Authorized Capital Increase against the
exchange, conveyance, transfer and assignment of all (but not less than all) of the vested and unvested Shares held by (or for the benefit of) MD Anderson (after giving effect to any and all adjustments in accordance with Section 1(f) and/or
Section 2(c) determined as of the date of delivery of the Put Election Notice or Call Election Notice, as 

 
applicable) at the time of the Termination License Event, with the intent that all unvested Initial Shares held by or for the benefit of MD Anderson shall be accelerated for purposes of the
Put Option. MD Anderson may exercise its Put Option by giving written notice of such exercise to Parent, substantially in the form attached hereto as Appendix I (the “Put Election Notice”). Parent may exercise its Call
Option by giving written notice of such exercise to MD Anderson, substantially in the form attached hereto as Appendix II (the “Call Election Notice”). In the event that the Put Option or Call Option has been exercised,
the parties shall use their reasonable best efforts to cause such acceleration of the vesting of Initial Shares to occur in a manner and at a time that allows MD Anderson the ability to participate in the Parent Exit Event with respect to its
Initial Shares. Notwithstanding any acceleration of vesting in accordance with this Exhibit C, nothing herein shall relieve, or be deemed to relieve, MD Anderson of its obligations to render services and otherwise perform in accordance with the
Collaboration Agreement following the exercise of the Put Option or the Call Option. 

Section 1.3    Number of Shares of Parent Common Stock. The number of shares of Parent Common Stock to be
issued to MD Anderson out of the Authorized Capital Increase following the exercise of the Put Option or Call Option shall be equal to the product of (i) the number of Exchangeable Shares, multiplied by (ii) the then applicable Exchange
Ratio (calculated to the nearest whole share of Parent Common Stock) (the number of shares of Parent Common Stock to be issued to MD Anderson the “Subscription Shares”). Notwithstanding anything to the contrary herein, Parent
and MD Anderson acknowledge and agree that, in connection with any Parent Exit Event, the amount of proceeds payable to MD Anderson with respect to the Parent Common Stock issued to MD Anderson as a result of the exercise of the Exchange Option
(including any shares of Parent Common Stock issued following the Subsequent Determination Date to MD Anderson as Milestone Shares in accordance with the last sentence of Section 2(a) of the Agreement) shall in no event exceed, as a percentage
of the total amount of proceeds payable to all equityholders of Parent with respect to their equity ownership of Parent, MD Anderson’s ownership percentage of the Company on a fully diluted basis (represented by the Exchangeable Shares,
including any shares of Parent Common Stock issued following the Subsequent Determination Date to MD Anderson as Milestone Shares in accordance with the last sentence of Section 2(a) of the Agreement) immediately prior to the consummation of
the Exchange Option (assuming all shares of Parent Common Stock issued following the Subsequent Determination Date to MD Anderson as Milestone Shares in accordance with the last sentence of Section 2(a) of the Agreement were issued and
outstanding immediately prior to the consummation of the Exchange Option). By way of illustration, if the Exchangeable Shares owned and held by MD Anderson constituted a [***] ownership interest in the Company (on a fully diluted basis) at the time
the Exchange Option was consummated, MD Anderson would be entitled to receive no more than [***] of the total amount of proceeds payable to all the equityholders of Parent in connection with a Parent Exit Event solely with respect to their ownership
of stock in Parent. For the avoidance of doubt, the total proceeds payable to equityholders of Parent shall not take into account any distributions or payments to equityholders of Parent to the extent not directly attributable to their stock
ownership. The foregoing limitation shall be set forth in the Transfer Documents. 
 Section 1.4    Notice
of ELSA Event, Parent Exit Event or Termination License Event. 
  

	 	(a)	 Parent and the Company will send MD Anderson a notice (the “ELSA Event Notice”) of
(i) each modification or amendment to the ELSA, (ii) any reduction in rights in the license provided to the Company pursuant to Section 7.1 of the ELSA, and (iii) the termination of the ELSA, in each case within five
(5) business days of the effective date of the occurrence of actions described in Section 1.4(a)(i)- Section 1.4(a)(iii), inclusive (the “ELSA Event”), specifying the nature and detailed description of the ELSA
Event. 

  

	 	(b)	 In the event Parent or its shareholders intend to consummate a Parent Exit Event or a Termination License Event
has occurred, Parent will send or cause to be sent to MD 

	 	
Anderson a written notice specifying the nature of the contemplated Parent Exit Event or the nature and occurrence of the Termination License Event, the anticipated date of the consummation of
such Parent Exit Event or the anticipated effective date of the Termination License Event, the anticipated consideration per share of Parent Common Stock in such Parent Exit Event, the FMV of the Parent Common Stock as of the Termination License
Event, and such other information material for the purposes of deciding whether or not to exercise the Put Option (the “Parent Exit Event Notice”). Notwithstanding anything to the contrary contained herein, if an ELSA Event
constitutes a Termination License Event, MD Anderson may request that the Parent send a Parent Exit Event Notice to MD Anderson with all of the information required by Section 1.4(a) and (b). If Parent and the Company fail to provide an ELSA
Event Notice with respect to an ELSA Event that constitutes a Termination License Event within ten (10) days of the effective date of the Termination License Event, then MD Anderson can send the Parent Exit Event Notice to Parent, and Parent
shall be required to provide all information that is required to be included within the Parent Exit Event Notice (the “Required Information”) to MD Anderson within ten (10) days of Parent’s receipt of the Parent
Exit Event Notice (or, if Parent disputes that the ELSA Event in question constitutes a Termination License Agreement, within ten (10) days of final determination that the ESLA Event in question constitutes a Termination License Event, whether
by agreement of the parties or final and binding judgment). MD Anderson may exercise its Put Option by serving the Put Election Notice to Parent (I) within thirty-five (35) days after delivery by Parent of the Parent Exit Event Notice, or
(II) within thirty-five (35) days after receipt of the Required Information in the event MD Anderson delivered the Parent Exit Event Notice to Parent, and Parent may exercise its Call Option by serving the Call Election Notice to MD
Anderson within thirty-five (35) days after delivery of the Parent Exit Event Notice, whereby Parent may include the Call Election Notice in the Parent Exit Event Notice. For the avoidance of doubt, neither MD Anderson nor Parent may elect to
exercise the Put Option or the Call Option, respectively, after expiration of the thirty-five (35) day election period described above, unless Parent fails to provide MD Anderson with the information required to be included in the Parent Exit
Event Notice. Parent shall use commercially reasonable efforts to provide MD Anderson such other information that MD Anderson reasonably requests and that is reasonably necessary to enable MD Anderson to make its decision whether or not to exercise
its Put Option. 

 Section 1.5    Authorized Capital Increase. 

 

	(a)	 As soon as practicable after the service of the Put Election Notice or the Call Election Notice, the Managing
Directors of Parent shall resolve with the approval of the Board to increase the share capital of Parent out of the Authorized Capital in return for contributions in kind by the issue of the Subscription Shares against the exchange, conveyance,
transfer and assignment of all of the Shares held by (or for the benefit of) (including the unvested shares) MD Anderson at such time; only MD Anderson shall be invited to subscribe for the new shares of Parent Common Stock issued out of the
Authorized Capital Increase under exclusion of the statutory subscription rights of the shareholders of Parent (the “Authorized Capital Increase”). 

 

	(b)	 The Managing Directors of Parent shall provide to MD Anderson a copy (including by e-mail) of the Authorized Capital Increase immediately after resolving the Authorized Capital Increase (the “Execution Notice”). Immediately after receipt of the Execution Notice, MD Anderson
shall 

  

	 	(i)	 at Parent’s sole expense, subscribe for the Subscription Shares by way of a notarially certified
subscription declaration pursuant to Section 55 para. 1 of the German Law Pertaining to Companies with Limited Liability (GmbHG) (the “Subscription Declaration”) and transmit to Parent the original of the
Subscription Declaration; 

	 	(ii)	 become a party in the form required by applicable law to such investment agreements, shareholders’
agreements and related agreements among the holders of at least a majority of Parent’s outstanding capital stock and, if applicable, Parent in the version applicable as of such time with the rights, privileges and obligations applicable to the
other holders of shares of Parent Common Stock, which contains inter alia transfer restrictions, voting agreements and liquidation and trade sale preferences and preferred dividends in favor of the holders of shares issued to the financial
investors of the Company; 

  

	 	(iii)	 date, complete, execute and deliver to Parent, with a copy to the Company, a stock assignment as necessary for
the exchange, conveyance, transfer and assignment of the Exchangeable Shares and all rights, title and interest therein or related thereto to Parent in exchange for the Subscription Shares and to exchange, convey, transfer and assign the
Exchangeable Shares to Parent as contribution in kind for the issuance of the Subscription Shares out of the Authorized Capital Increase, and Parent shall have the right to transfer to its own name all such Exchangeable Shares without further action
by MD Anderson; and 

  

	 	(iv)	 execute and deliver any other documents and instruments to which other holders of shares of Parent Common Stock
are a party or that are reasonably necessary for the valid transfer of the Exchangeable Shares or the consummation of the Parent Exit Event or as required pursuant to Section 1(d) and/or Section 2 of the Restricted Stock Acquisition
Agreement 

 (such documents set forth under (i) through (iv) the “Transfer Documents”). 

Section 1.6    Record of the Transfer of Exchangeable Shares. Following the execution and delivery of the
Transfer Documents to Parent, the Company shall record the transfer of the Exchangeable Shares in its registries. 

Section 1.7    Registration with the Commercial Register. The Managing Directors of Parent shall apply
for registration of the Authorized Capital Increase with the Commercial Register of Parent immediately after receipt of the Transfer Documents. 

Section 1.8    Consummation of the Parent Exit Event. In the event that within 120 days after the date on
which the Managing Directors of Parent resolve the Authorized Capital Increase, the Parent Exit Event has not been consummated (or, if the Put Option was exercised in connection with a proposed Termination License Event and a Termination License
Event has not occurred within such 120 day period), the parties are entitled to be restored to the position they were in prior to the exercise of the Put Option or Call Option, respectively. 

Section 1.9    Determination of FMV. Parent may from time to time engage an Appraiser to determine the
FMV of the Exchangeable Shares and/or shares of Parent Common Stock. If no determination of FMV has been made for either the Exchangeable Shares or the Parent Common Stock within the six (6) month period prior to receipt by Parent of a Put
Election Notice or receipt by MD Anderson of a Call Election Notice or Parent Exit Event Notice, Parent shall promptly engage the Appraiser to determine FMV of the Exchangeable Shares and/or Parent Common Stock. In connection with any engagement of
the Appraiser under this Section 1.9, (i) Parent shall notify the Appraiser of the definition of FMV contained herein, (ii) Parent and the Company will provide information to the Appraiser (and, subject to customary confidentiality
obligations, with a copy to MD Anderson) as such Appraiser may reasonably request, and (iii) all costs and expenses of such Appraiser shall be paid by the Company. The Appraiser 

 
shall inform Parent and MD Anderson in writing of its determination of FMV, including a report describing the methodologies and underlying assumptions. Absent manifest error, the determination by
the Appraiser shall be final and conclusive on Parent, the Company and MD Anderson. 

Section 1.10    Status of Exchangeable Shares Prior to Exercise of Exchange Options.  

 

	(a)	 Until such time that the Put Option or Call Option is exercised in accordance herewith, (i) the
Exchangeable Shares shall continue to be equity securities of the Company, with all of the rights and privileges appurtenant thereto under the Company’s organizational documents and applicable laws; and (ii) neither MD Anderson nor any
successor shall be entitled to vote or receive dividends or exercise any other rights as a shareholder in the Parent. 

  

	(b)	 Until such time that the Put Option or Call Option is exercised in accordance herewith, all dividends on the
Exchangeable Shares (if any) shall be paid directly to MD Anderson and shall not be held in escrow. In the event of any stock dividend, stock split, recapitalization or other change affecting the Exchangeable Shares, any new, substituted or
additional securities or other property which is by reason of such transaction distributed with respect to the Exchangeable Shares shall be considered Exchangeable Shares subject to this Agreement. 

Section 1.11    Representation Regarding Liquidation Preferences in an IPO. Parent hereby represents and
warrants that, as of the date hereof, no liquidation preferences of any of the shareholders of Parent (including without limitation, the Series C shareholders and the Series D shareholders) are payable in connection with a Parent IPO. 

Section 1.12    Specific Enforcement; Proxy. 

 

	(a)	 It is the intention of the parties that MD Anderson, upon exercise of the Put Option pursuant to the terms of
this Exhibit C, shall be entitled to receive the Subscription Shares in specie. It is the further intention of the parties that Parent, upon exercise of the Call Option pursuant to the terms of this Exhibit C, shall be entitled to receive the
Exchangeable Shares in specie. Furthermore, it is expressly agreed between the parties that money damages are inadequate to compensate MD Anderson for the Subscription Shares or Parent for the Exchangeable Shares and, therefore, that each shall,
upon proper exercise of the Exchange Option, be entitled to specific enforcement of its rights to receive said shares. 

  

	(B)	 Each of MD Anderson and Parent hereby constitutes and appoints as the proxy of such party and hereby grants a
power of attorney to the President of the Company, with full power of substitution, with respect to the matters set forth in this Exhibit C, and hereby authorizes each of them to represent, vote, execute and deliver documents, and take any and all
other actions if and only if such party is in material breach of its obligations under this Exhibit C and such material breach remains uncured for a period of five (5) calendar days after notice by the other party with respect to such material
breach. Each of the proxy and power of attorney granted pursuant to the immediately preceding sentence is given in consideration of the agreements and covenants of MD Anderson and Parent in connection with the transactions contemplated by this
Exhibit C and, as such, each is coupled with an interest and shall be irrevocable unless and until this Agreement terminates or expires. 

 APPENDIX I 

PUT ELECTION NOTICE 
 [immatics
biotechnologies GmbH] 
 [Address] 
 Attention: Managing
Director 
 Dear [immatics biotechnologies GmbH Managing Director]: 

1. Definition. Reference is hereby made to Exhibit C Terms and Conditions of Put-Call Option (the “Put-Call Agreement”) of that certain Restricted Stock Acquisition Agreement dated as of the [    ] day of August, 2015, by and among IMMATICS US,
INC. (the “Company”), THE BOARD OF REGENTS OF THE UNIVERSITY OF
TEXAS SYSTEM, FOR THE BENEFIT OF THE UNIVERSITY OF TEXAS M. D. ANDERSON
CANCER CENTER (“MD Anderson”), and IMMATICS BIOTECHNOLOGIES GMBH (the “Parent”). Capitalized terms
used herein without definition shall have the respective meaning assigned to such terms in the Put-Call Agreement or, if not defined in the Put-Call Agreement, the
meanings assigned to such terms in the Restricted Stock Acquisition Agreement. 
 2. Exercise of the Put Option. Pursuant to Section 1.2
of the Put-Call Agreement, the undersigned hereby elects to exchange                 1 Exchangeable Shares of Immatics US, Inc. for the corresponding number of shares of Parent Common Stock based on the applicable Exchange Ratio as of the date hereof. 

3. Rights as Stockholder. Until the Authorized Capital Increase is registered with the Commercial Register of the Company, no right to vote or receive
dividends as a shareholder of the Parent shall exist with respect to the shares of Parent Common Stock, notwithstanding the exercise of the Put Option. No adjustment will be made for a dividend or other right for which the record date is prior to
the date the Authorized Capital Increase is registered with the Commercial Register of the Company. 
  

			
	By:	 	  

			
		
	Name:	 	  

			
		
	Title:	 	  

  
 1 Note: number of all shares held by MD Anderson to be inserted (including any unvested Shares that have been accelerated). 

 APPENDIX II 

CALL ELECTION NOTICE 
 [MD Anderson] 

[Address] 
 Dear Sir, Madam: 

1. Definition. Reference is hereby made to Exhibit C Terms and Conditions of Put-Call Option (the “Put-Call Agreement”) of that certain Restricted Stock Acquisition Agreement dated as of the [    ] day of August, 2015, by and among IMMATICS US,
INC. (the “Company”), THE BOARD OF REGENTS OF THE UNIVERSITY OF
TEXAS SYSTEM, FOR THE BENEFIT OF THE UNIVERSITY OF TEXAS M. D. ANDERSON
CANCER CENTER (“MD Anderson”), and IMMATICS BIOTECHNOLOGIES GMBH (the “Parent”). Capitalized terms
used herein without definition shall have the respective meaning assigned to such terms in the Put-Call Agreement or, if not defined in the Put-Call Agreement, the
meanings assigned to such terms in the Restricted Stock Acquisition Agreement. 
 2. Exercise of the Call Option. Pursuant to Section 1.2
of the Put-Call Agreement, Parent hereby elects to acquire
                2 Exchangeable Shares of Immatics US, Inc. held by MD Anderson for the corresponding number
of shares of Parent Common Stock based on the applicable Exchange Ratio as of the date hereof. 
 3. Rights as Stockholder. Until the Authorized
Capital Increase is registered with the Commercial Register of the Company, no right to vote or receive dividends as a shareholder of the Parent shall exist with respect to the shares of Parent Common Stock, notwithstanding the exercise of the Call
Option. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Authorized Capital Increase is registered with the Commercial Register of the Company. 

 

			
	IMMATICS BIOTECHNOLOGIES GMBH

 
			
		
	By:	 	  

 
			
	Name:	 	  

 
			
	Title:	 	  

  
  

2 Note: number of all shares held by MD Anderson to be inserted (including any unvested Shares that have
been accelerated).

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00307-of-00352.parquet"}]]